Document:

Exhibit 10.4

 

EXECUTION VERSION

 

THIRD AMENDMENT AND CONSENT TO LOAN AND SECURITY
AGREEMENT

 

This THIRD AMENDMENT AND CONSENT TO LOAN AND
SECURITY AGREEMENT (this “Amendment”), dated as of September 30, 2020 (the “Third Amendment Date”),
is by and among METUCHEN PHARMACEUTICALS LLC, a Delaware limited liability company (“Metuchen”), Pos-T-Vac, LLC, a
Delaware limited liability company (“PTV”), and Timm Medical Technologies, Inc., a Delaware corporation (“Timm”,
and together with Metuchen and PTV, collectively, jointly and severally, the “Borrower”), the several banks and other
financial institutions or entities party hereto as lenders (collectively, referred to as “Lender”) and HERCULES CAPITAL,
INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and Lender (in such capacity, the
 “Agent”).

 

WHEREAS, Borrower, Lender and the Agent
are parties to a certain Loan and Security Agreement, dated as of September 30, 2016, as amended by that certain First Amendment to Loan
and Security Agreement dated November 22, 2017 and Second Amendment to Loan and Security Agreement dated April 13, 2020 (and as the same
may from time to time be further amended, modified or supplemented in accordance with its terms, the “Loan Agreement”);

 

WHEREAS, in accordance with Section 11.3
of the Loan Agreement, Borrower, Lender and the Agent desire to amend the Loan Agreement as provided herein;

 

WHEREAS, pursuant to that certain Agreement
and Plan of Merger, dated as of May 17, 2020 (the “Merger Agreement”), among Borrower, Petros Pharmaceuticals, Inc.
(“Parent”), PM Merger Sub 1, LLC (“Merger Sub 1”), PN Merger Sub 2, Inc. (“Merger Sub 2”)
and Neurotrope, Inc. (“Neurotrope”), Neurotrope and Borrower have formed, directly or indirectly, (a) Parent, (b) Merger
Sub 1 and (c) Merger Sub 2, and each of the parties to the Merger Agreement shall effect the following mergers upon the terms and conditions
set forth therein: (i) Merger Sub 1 shall be merged with and into Borrower (the “Metuchen Merger”), with Borrower surviving
as a direct wholly owned subsidiary of Parent and (ii) simultaneous with the Metuchen Merger, Merger Sub 2 shall be merged with and into
Neurotrope (the “Neurotrope Merger” and, together with the Metuchen Merger, the “Mergers”), with
Neurotrope surviving as a direct wholly owned subsidiary of Parent. For purposes of this Amendment, the Mergers and the transactions contemplated
by the Merger Agreement shall be referred to as the “Merger Transactions”); and

 

WHEREAS, Borrower requests that the Agent
and Lender consent to the Merger Transactions and the Agent and Lender hereby consent to the Merger Transactions, as set forth in Section
3 of this Amendment and on the terms and conditions set forth herein.

 

NOW THEREFORE, in consideration of the mutual
agreements contained in the Loan Agreement and herein and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto hereby agree as follows:

 

1.       Defined
Terms. Terms not otherwise defined herein which are defined in the Loan Agreement shall have the same respective meanings herein
as therein.

 

2.       Amendments
to Loan Agreement. Subject to the satisfaction of the conditions set forth in Section 4 of this Amendment, as of the Third Amendment
Date, the Loan Agreement is hereby amended as follows:

 

(a)           The
Loan Agreement shall be amended by inserting the following new definitions to appear alphabetically in Section 1.1 thereof:

 

   “Amortization Date III”
means November 1, 2020; provided that, in the event that, as of as of said date (i) Borrower has not achieved Financing Milestone II and
(ii) no Event of Default has occurred and is continuing, the Amortization Date III shall be extended to December 1, 2020; and provided
further that in the event that, as of said date (x) Borrower has not achieved Financing Milestone II and (y) no Event of Default has occurred
and is continuing, the Amortization Date III shall be extended to January 1, 2021.

 

    1

     

    

 

“Catch Up Payment” means
$509,935.78; provided that, in the event that Amortization Date III is extended to December 1, 2020, the Catch Up Payment shall be increased
to $1,022,303.43; and provided further that, in the event that Amortization Date III is extended to January 1, 2021, the Catch Up Payment
shall be increased to $1,542,036.28.

 

“Third Amendment” means
that Third Amendment and Consent to Loan and Security Agreement dated the Third Amendment Date by and among Borrower, Lender and Agent.

 

“Third Amendment Date”
means September 30, 2020.

 

(b)       The
Loan Agreement shall be amended by amending and restating the following definitions in Section 1.1 thereof to read as follows:

 

“Escrow Agreement” means
the Escrow Agreement dated September 30, 2020 by and among Agent, Juggernaut Capital Partners III, L.P., a Cayman Islands limited partnership
(“Juggernaut”), and Wells Fargo, N.A., as the same may from time to time be amended, modified, supplemented or restated.

 

“Financing Milestone II”
means (i) no default or Event of Default shall have occurred and be continuing and (ii) Borrower shall have received, after March 31,
2020 and on or prior to December 21, 2020, unrestricted (including not subject to any clawback, redemption, escrow or similar contractual
restriction) net cash proceeds in an aggregate amount of at least $25,000,000, which proceeds shall be immediately deposited in a Deposit
Account or Investment Account of Borrower subject to an Account Control Agreement in favor of Agent, from (A) the sale of equity interests
of Metuchen and/or Subordinated Indebtedness (inclusive of amounts raised to satisfy Financing Milestone I) and (B) a merger, acquisition
or similar transaction involving Borrower.

 

“Loan Documents” means
this Agreement, the Notes (if any), the ACH Authorization, the Account Control Agreements, the Joinder Agreements, the Collateral Assignment
of Contracts, the Collateral Assignment of Intellectual Property, all UCC Financing Statements, the Guaranty, the Escrow Agreement and
any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby, as the same may from
time to time be amended, modified, supplemented or restated

 

“Term Loan Maturity Date”
means April 1, 2021, provided that, if Borrower shall have achieved Financing Milestone II, then the Term Loan Maturity Date shall be
extended to December 1, 2021.

 

(c)       The
Loan Agreement shall be amended by amending and restating Section 2.2(d) in its entirety, and inserting in lieu thereof the following:

 

“(d)    Payment.
Borrower will pay interest on the Term Loan Advance on the first Business Day of each month, beginning November 1, 2016. Borrower
shall repay the aggregate Term Loan principal balance that is outstanding on the day immediately preceding the Amortization Date
(excluding all accrued PIK Interest added to such principal balance prior to such date), in equal monthly installments of principal
and interest (mortgage style) based on a 36-month amortization period beginning on the Amortization Date and continuing on the first
Business Day of each month thereafter until the Second Amendment Date. Commencing on the Second Amendment Date, Borrower shall repay
the remaining Term Loan principal balance (including all accrued PIK Interest added to such principal balance as of the Second
Amendment Date) in equal monthly installments of principal and interest (mortgage style) based on a 20-month amortization period
beginning on Amortization Date II and continuing on the first Business Day of each month thereafter until the Third Amendment Date.
Commencing on the Third Amendment Date, Borrower will pay interest on the remaining Term Loan principal balance on the first
Business Day of each month, beginning October 1, 2020. On or before the third Business Day after achieving Financing Milestone II,
Borrower shall make a payment equal to the Catch Up Payment for application to the reduction of the outstanding Term Loan principal
balance; provided that if Financing Milestone II is not achieved on or prior to December 21, 2020, Borrower or Juggernaut, on behalf
of Borrower pursuant to the terms of the Escrow Agreement, shall make a payment equal to the Catch Up Payment on December 22, 2020.
Borrower shall repay the remaining Term Loan principal balance in equal monthly installments of principal and interest (mortgage
style) based on a 15-month amortization period (the “Monthly Installments”) beginning on Amortization Date III
and continuing on the first Business Day of each month thereafter until the Secured Obligations (other than inchoate indemnity
obligations) are repaid (which for the avoidance of doubt, may include a bullet payment of the remaining outstanding principal
balance on the Term Loan Maturity Date. If, for any fiscal year of Borrower, there shall be Excess Cash Flow, Borrower shall, on the
relevant Excess Cash Flow Application Date (as hereinafter defined), apply an amount equal to 75% of such Excess Cash Flow toward
the prepayment of the Term Loan. Each such prepayment from Excess Cash Flow shall be made on a date (each an “Excess Cash
Flow Application Date”) occurring no later than the date on which the financial statements of Borrower referred to in
Section 7.1 for the fiscal year with respect to which such prepayment is made, are required to be delivered to Lender. Prepayments
of the Term Loan from Excess Cash Flow shall be applied to reduce the remaining Monthly Installments on a pro rata basis. The entire
Term Loan principal balance (including all accrued PIK Interest added to the principal balance) and all accrued but unpaid interest
hereunder, shall be due and payable on the Term Loan Maturity Date. Borrower shall make all payments under this Agreement without
setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to
Borrower’s account as authorized on the ACH Authorization (i) on each payment date of all periodic obligations payable to
Lender under the Term Advance and (ii) in connection with out-of-pocket legal fees and costs incurred by Agent or Lender in
connection with Section 11.11 of this Agreement. Once repaid, the Term Loan Advance or any portion thereof may not be
reborrowed.

 

(d)       The
Loan Agreement shall be amended by amending and restating Section 8.2 to read as follows:

 

    2

     

    

 

“SECTION 8.     FINANCIAL COVENANTS.

 

8.2       Minimum
Cash.  Borrower shall be required to maintain unrestricted Cash in a Deposit Account or Investment Account subject to an Account Control
Agreement in favor of Agent, at all times during the applicable “Minimum Cash Covenant Period” set forth in the schedule below,
subject to Borrower’s achievement of the “Minimum Net Revenue” and “Minimum EBITDA” for the applicable Test
Period, in the following amounts: (i) if Borrower fails to achieve both the Minimum Net Revenue and Minimum EBITDA for a given Test Period,
an amount greater than or equal to 100% of the Secured Obligations then outstanding during such Minimum Cash Covenant Period; (ii) if
Borrower achieves either the Minimum Net Revenue or Minimum EBITDA for a given Test Period, an amount greater than or equal to 50% of
the Secured Obligations then outstanding during such Minimum Cash Covenant Period; and (iii) if Borrower achieves both the Minimum Net
Revenue and Minimum EBITDA for a given Test Period, $0.

 

	Test Period	 	Minimum Net Revenue	 	 	Minimum EBITDA	 	 	Minimum Cash
 Covenant Period
	Six-month period ended September 30, 2020	 	$	6,000,000	 	 	$	(4,194,000	)	 	November 1, 2020 through January 31, 2020
	Six-month period ended December 31, 2020	 	$	7,170,000	 	 	$	(3,661,000	)	 	February 1, 2021 through April 30, 2021
	Six-month period ended March 31, 2021	 	$	10,098,000	 	 	$	(1,599,000	)	 	May 1,2021 through July 31, 2021
	Six-month period ended June 30, 2021	 	$	11,259,000	 	 	$	(867,000	)	 	August 1, 2021 through December 1, 2021

 

Borrower shall provide Agent evidence
of compliance with the financial covenant under this Section 8.2 upon request in form and substance reasonably acceptable to Agent and
supporting documentation requested by Agent.

 

    3

     

    

 

3.       Consent.
  Subject to and upon the satisfaction of the conditions specified in Section 4 hereof and the following proviso, Agent and Lender hereby
consent to the Merger Transactions so long as, on or prior to December 21, 2020, the Merger Transactions are consummated and each of the
 “Effective Times” (as defined in the Merger Agreement) shall have occurred. For the avoidance of doubt, if on or prior to
December 21, 2020 the Merger Transactions are not consummated or any of the “Effective Times” (as defined in the Merger Agreement)
have not occurred, the foregoing consent shall automatically terminate and shall be deemed to be null and void ab initio. In addition,
the foregoing consent shall be limited precisely as written and except as so provided shall not be deemed (a) to be a consent with respect
to any other matter, term, conditions or transaction or to prejudice any right or remedy which Lender may now have or may have in the
future under or in connection with the Loan Documents; (b) to be a consent to any future consent or modification, forbearance, or waiver
to the Loan Agreement or any other Loan Document, or to be any waiver of any of the provisions thereof; or (c) to limit or impair Lender’s
right to demand strict performance of all terms and covenants of the Loan Agreement as of any date.

 

4.       Conditions
to Effectiveness.   Borrower, Lender and the Agent agree that this Amendment shall become effective upon the satisfaction of the
following conditions precedent, each in form and substance satisfactory to the Agent:

 

(a)       The
Agent and Lender shall have received a fully-executed counterpart of this Amendment signed by Borrower;

 

(b)     The
Borrower, Agent, Juggernaut and Wells Fargo, N.A. shall have entered into an Escrow Agreement in form and substance satisfactory to Agent
on or prior to the Third Amendment Date;

 

(c)     Juggernaut
or Wells Fargo, N.A. shall have provided to Agent written evidence in form and substance satisfactory to Agent that Juggernaut shall have
delivered to Wells Fargo, N.A. in cash and in immediately available funds an amount not less than $1,542,036.28 pursuant to Section 1.1
of the Escrow Agreement on or prior to the Third Amendment Date and such amount shall have been deposited into the applicable escrow account
established in connection therewith; and

 

(d)     The
Agent shall have received payment for all reasonable and documented fees and expenses incurred by Lender and the Agent in connection with
this Amendment, including, but not limited to, all legal fees and expenses, payable pursuant to Section 11.11 of the Loan Agreement.

 

5.       Representations
and Warranties.   Borrower hereby represents and warrants to Lender and the Agent as follows:

 

(a)       Representations
and Warranties in the Agreement.  The representations and warranties of Borrower set forth in Section 5 of the Loan Agreement are true
and correct in all material respects on and as of the date hereof, except to the extent such representations and warranties expressly
relate to an earlier date in which case they shall be true and correct in all material respects on and as of such earlier date.

 

(b)       Authority,
Etc.  The execution and delivery by Borrower of this Amendment and the performance by Borrower of all of its agreements and obligations
under the Loan Agreement and the other Loan Documents, as amended hereby, are within the limited liability company authority of Borrower
and have been duly authorized by all necessary limited liability company action on the part of Borrower. With respect to Borrower, the
execution and delivery by Borrower of this Amendment does not and will not require any registration with, consent or approval of, or notice
to any Person (including any governmental authority).

 

(c)       Enforceability
of Obligations.  This Amendment, the Loan Agreement and the other Loan Documents, as amended hereby, constitute the legal, valid and
binding obligations of Borrower enforceable against Borrower in accordance with their terms, except as enforceability is limited by bankruptcy,
insolvency, reorganization, moratorium, general equitable principles or other laws relating to or affecting generally the enforcement
of, creditors’ rights and except to the extent that availability of the remedy of specific performance or injunctive relief is subject
to the discretion of the court before which any proceeding therefor may be brought.

 

    4

     

    

 

(d)       No
Default.  Immediately after giving effect to this Amendment (i) no fact or condition exists that would (or would, with the passage
of time, the giving of notice, or both) constitute an Event of Default, and (ii) no event that has had or could reasonably be expected
to have a Material Adverse Effect has occurred and is continuing.

 

(e)       Event
of Default.  By its signature below, Borrower hereby agrees that it shall constitute an Event of Default if any representation or warranty
made herein should be false or misleading in any material respect when made.

 

6.       Reaffirmations.
  All of the terms and conditions of the Loan Agreement and the other Loan Documents as amended hereby remain in full force and effect.
Nothing contained in this Amendment shall in any way prejudice, impair or effect any rights or remedies of Lender or the Agent under the
Loan Agreement and the other Loan Documents. Except as specifically amended hereby, Borrower hereby ratifies, confirms, and reaffirms
all covenants contained in the Loan Agreement and the other Loan Documents. The Loan Agreement, together with this Amendment, shall be
read and construed as a single agreement. All references in the Loan Documents to the Loan Agreement or any other Loan Document shall
hereafter refer to the Loan Agreement or such other Loan Document as amended hereby.

 

7.       Release.
  In consideration of the agreements of Agent and each Lender contained herein and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, Borrower, on behalf of itself and its successors, assigns, and other legal representatives,
hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and each Lender, and its successors
and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys,
employees, agents and other representatives (Agent, Lenders and all such other persons being hereinafter referred to collectively as the
 “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action,
suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all
other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown,
suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives
may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance,
action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, for or on account of, or
in relation to, or in any way in connection with the Loan and Security Agreement, or any of the other Loan Documents or transactions thereunder
or related thereto. Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete
defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted
or attempted in breach of the provisions of such release. Borrower agrees that no fact, event, circumstance, evidence or transaction which
could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of
the release set forth above.

 

8.       Execution
in Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but
which together shall constitute one instrument.

 

9.       Miscellaneous.

 

(a)       THIS
AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (INCLUDING SECTIONS 5-1401
AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW, BUT EXCLUDING ALL OTHER CHOICE OF LAW AND CONFLICTS OF LAW RULES).

 

(b)       The
captions in this Amendment are for convenience of reference only and shall not define or limit the provisions hereof.

 

(c)       This
Amendment expresses the entire understanding of the parties with respect to the transactions contemplated hereby. No prior negotiations
or discussions shall limit, modify, or otherwise affect the provisions hereof.

 

    5

     

    

 

(d)       Any
determination that any provision of this Amendment or any application hereof is invalid, illegal or unenforceable in any respect and in
any instance shall not affect the validity, legality, or enforceability of such provision in any other instance, or the validity, legality
or enforceability of any other provisions of this Amendment.

 

[Signature Pages to Follow]

 

    6

     

    

 

IN WITNESS WHEREOF, Borrower, Lender and the Agent have duly
executed and delivered this Amendment as of the day and year first above written.

 

	 	BORROWER:
	 	 
	 	METUCHEN PHARMACEUTICALS
    LLC
	 	 
	 	Signature:	/s/
    Keith F. Lavan
	 	 	 
	 	Print Name:	Keith F. Lavan
	 	 	 
	 	Title:	CFO
	 	 
	 	 
	 	POS-T-VAC, LLC
	 	 
	 	Signature:	/s/
    Keith F. Lavan
	 	 	 
	 	Print Name:	Keith F. Lavan
	 	 	 
	 	Title:	CFO
	 	 
	 	 
	 	TIMM MEDICAL TECHNOLOGIES,
    INC.
	 	 
	 	Signature:	/s/ Keith F. Lavan
	 	 	 
	 	Print Name:	Keith F. Lavan
	 	 	 
	 	Title:	CFO

 

[Signature Page to Third LSA Amendment]

 

    

     

    

 

	Accepted in Palo Alto, California:
	 	AGENT:	 
	 	 	 
	 	HERCULES CAPITAL, INC.
	 	 
	 	Signature:	/s/ Jennifer Choe
	 	 	 
	 	Print Name:	Jennifer Choe
	 	 	 
	 	Title:	Associate General Counsel
	 	 	 
	 	 	 
	 	LENDER:	 
	 	 	 
	 	HERCULES FUNDING II, LLC
	 	 	 
	 	Signature:	/s/ Jennifer Choe
	 	 	 
	 	Print Name:	Jennifer Choe
	 	 	 
	 	Title:	Associate General Counsel

 

[Signature Page to Third LSA Amendment]Exhibit 10.9

 

CONFIDENTIAL

 

LICENSE AGREEMENT

 

Dated as of March 24, 2020

 

between

 

METUCHEN PHARMACEUTICALS LLC

 

and

 

HYBRID MEDICAL LLC

 

     

     

    

 

CONFIDENTIAL

 

TABLE OF CONTENTS

 

		1.	DEFINITIONS.	3
	 	 	 	 

		2.	RIGHTS AND RESTRICTIONS.	9
	 	 	 	 

		3.	RESPONSIBILITIES OF PARTIES.

                                                                                 
	11

		4.	PAYMENT TERMS.	14
	 	 	 	 

		5.	REPRESENTATIONS, WARRANTIES AND COVENANTS.	18
	 	 	 	 

		6.	TERM AND TERMINATION.

                                                                                 
	22

		7.	OWNERSHIP AND OTHER PROPRIETARY RIGHTS.	25
	 	 	 	 

		8.	CONFIDENTIALITY.	31
	 	 	 	 

		9.	INDEMNIFICATION AND INSURANCE.	33
	 	 	 	 

		10.	LIMITATION ON LIABILITY.	35
	 	 	 	 

		11.	DISPUTE RESOLUTION.	36
	 	 	 	 

		12.	MISCELLANEOUS.	37

 

METUCHEN/HYBRID DEVELOPMENT
AND LICENSE AGREEMENT

 

    Page  1

     

    

 

CONFIDENTIAL

 

SCHEDULES

 

Schedule 1         HYBRID Patents

 

     2

     

    

 

CONFIDENTIAL

 

LICENSE AGREEMENT

 

This License
Agreement (this “Agreement”) is signed by HYBRID MEDICAL, LLC (including any affiliates) (“HYBRID”) and METUCHEN
PHARMACEUTICALS LLC (“METUCHEN”) as of March 24th,
2020 (“Effective Date”) METUCHEN and HYBRID are sometimes referred to herein individually as a “Party” and collectively
as the “Parties.”

 

RECITALS

 

WHEREAS, HYBRID
is engaged in the development of, and is the owner of certain, technology and intellectual property rights in the area topical applications
containing emu oil, nicardipine and superoxide dismutase as active pharmaceutical ingredients for treatment of Peyronie’s disease
or any Product resulting from the Option herein (“Product”);

 

WHEREAS, METUCHEN
develops, markets, distributes and sells pharmaceutical products; and

 

WHEREAS, METUCHEN
and HYBRID desire to collaborate on the development and commercialization of such PRODUCT for the treatment of Peyronie’s disease
and additional indications as described further herein;

 

NOW, THEREFORE,
in consideration of the mutual promises and covenants hereinafter set forth, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, METUCHEN and HYBRID agree to the foregoing and as follows:

 

1.            
DEFINITIONS. Each of the capitalized terms used in this Agreement (other than the headings of the Sections), whether used
in singular or plural form, shall have the meaning ascribed to each in this Agreement or as set forth below.

 

1.1             
“Action” means, with respect to the applicable Party having such right pursuant to Section 7.11 (Enforcement), any
action that such Party reasonably deems appropriate including notifying the infringer to cease and desist all such Infringing Activity,
filing a complaint and instituting a lawsuit.

 

1.2             
“Affiliate” means any individual, corporation or other legal entity which a Party directly or indirectly through one
or more intermediaries controls or which is controlled by or under common control with such Party. For the purpose of this definition,
 “control” means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies
of an individual, corporation or other legal entity, whether through the ownership of voting securities, by contract, or otherwise.

 

1.3            
 “Anti-Corruption Laws” means the U.S. Foreign Corrupt Practices Act (15 U.S.C. §§78dd-1, et. seq.), as
amended, the Organization for Economic Co-operation and Development (OECD) Convention on combating bribery of foreign public
officials in international business transactions, and any other applicable anti-corruption laws.

 

     3

     

    

 

CONFIDENTIAL

 

1.4             
“Change of Control” of METUCHEN means: (a) a merger, reorganization or consolidation of METUCHEN with a Third Party
which results in the voting securities of METUCHEN outstanding immediately prior thereto ceasing to represent at least fifty percent (50%)
of the combined voting power of the surviving entity immediately after such merger, reorganization or consolidation; (b) a Third Party
becoming the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of METUCHEN; or
(c) the sale or other transfer of all or substantially all of METUCHEN’s business or assets.

 

 1.5              “Confidential Information” has the meaning as set forth herein.

 

1.6             
“Control” or “Controlled” means, in the context of a license to or ownership of intellectual property,
possession of the ability on the part of a Party to grant access to or a license or sublicense as provided for herein without violating
the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant
the other Party such access or license or sublicense.

 

1.7             
“Current Good Clinical Practice” means the applicable current good clinical practices promulgated by the FDA or other
applicable Regulatory Agency in any region or country other than the United States, including any applicable requirements of Title 21
of the Code of Federal Regulations.

 

1.8             
“Current Good Laboratory Practice” means the applicable current good laboratory practices promulgated by the FDA or
other applicable Regulatory Agency in any region or country other than the United States, including any applicable requirements of Title
21 of the Code of Federal Regulations.

 

1.9             
“Current Good Manufacturing Practices” or “cGMP” means the applicable current good manufacturing practices
promulgated by the FDA or other applicable Regulatory Agency in any region or country other than the United States, including any applicable
requirements of Title 21 of the Code of Federal Regulations.

 

1.10             
“Customer” means any Person that is not an Affiliate of METUCHEN and purchases Product(s) from METUCHEN or its Affiliates.

 

1.11             “Developed
Data” means that portion of the Work Product that consists solely of data resulting from pre-clinical and clinical trials conducted
in connection with the Product and which was funded by METUCHEN.

 

1.12             “Development
Plan” means the development plan and budget mutually agreed in writing by the Parties for the development of a Product by HYBRID
for METUCHEN under this Agreement.

 

 1.13              “Excluded Person” means an Ineligible Person or a Person on an Exclusion List.

 

1.14              “Exclusion
Lists” mean: (a) the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://www.oig.hhs.gov);
(b) the General Services Administration’s List of Parties Excluded from Federal Programs (available through the Internet at http://www.epls.gov);
and (c) the FDA Debarment List (available through the Internet at http://www.fda.gov/ora/compliance ref/debar/).

 

     4

     

    

 

CONFIDENTIAL

 

1.15             
“Export Control Laws” means: (a) all applicable U.S. laws and regulations relating to sanctions and embargoes imposed
by U.S. Department of Treasury’s Office of Foreign Assets Control (or its successor office or other body having substantially the
same function); (b) all applicable U.S. export control laws, including the Arms Export Controls Act (22 U.S.C. Ch. 39), the International
Emergency Economic Powers Act (50 U.S.C. §§ 1701 et seq.), the Trading With the Enemy Act (50 U.S.C. app. §§ 1 et
seq.), the Export Administration Act of 1979 (50 U.S.C. app. §§ 2401 et seq.), International Boycott Provisions of Section 999
of the U.S. Internal Revenue Code of 1986, and all rules, regulations and executive orders relating to any of the foregoing, including
but not limited to the International Traffic in Arms Regulations (22 C.F.R. §§ 120 et seq.), the Export Administration Regulations
(15 C.F.R. §§ 730 et. seq.), and the regulations administered by the Office of Foreign Assets Controls of the United States
Department of the Treasury; and (c) all export controls imposed on any Product by any country or organization or nation within the jurisdiction
in which Licensee operates or does business

 

1.16             
 “FDA” means the United States Food and Drug Administration or any successor entity.

 

1.17              “Field” means treatment of
Peyronie’s disease and, any additional fields in which Metuchen actually pays for an Option to exercise a license for
additional treatments covered by the Patent Rights.

 

1.18             
“First Commercial Sale” of a Product means the first sale for use or consumption by the general public of such Product
in a country after Marketing Approval and, if required for commercial sale, Price Approval, has been granted by the governing health authority
of such country.

 

1.19             
“First Product” means the first Product that METUCHEN sells under this Agreement for use or consumption by the general
public after Marketing Approval has been granted by the FDA for such first Product.

 

1.20             
“Force Majeure” means if the performance by either Party of any obligation under this Agreement is wholly or partially
prevented, restricted, interfered with or delayed and the cause or causes are not due to, or caused by, any action or inaction of the
Party claiming the benefit of force majeure or are not reasonably within the control of the Party claiming the benefit of force majeure,
including acts of God, terrorism, acts by a Governmental Authority or Regulatory Agency, floods, fires, civil commotion, embargoes, quotas,
or any delays or detention by customs, health or other Government Authorities.

 

1.21             
“GAAP” means generally accepted accounting principles in effect in the United States at the applicable time. GAAP shall
be applied by the Parties in a consistent manner.

 

1.22             
“Governmental Authority” means any court, tribunal, arbitrator, agency, legislative body, commission, official or other
instrumentality of: (a) any government of any country; or (b) a federal, state, province, county, city or other political subdivision
thereof.

 

     5

     

    

 

CONFIDENTIAL

 

 1.23              “HYBRID New Patents” means any Patents from a HYBRID New Invention.

 

1.24             
“HYBRID New Invention” means any invention conceived or reduced to practice solely by HYBRID which is in the category
of the Field of Use and covered by a Valid Claim of the HYBRID Patents licensed herein.

 

1.25             
“HYBRID Know-How” means any and all scientific, medical, technical, marketing, and regulatory information, know-how,
trade secrets, inventions, discoveries, technology, modifications, improvements or the like (including clinical, safety, toxicity, analytical
and technical data, assays, and analytical methods), that is or relates to (a) the HYBRID Technology, and (b) the formulations, tolerability,
compatibility and stability of the Product(s), and is owned or Controlled by HYBRID or its Affiliates as of the Effective Date or at any
time until the Launch Date of the First Product and is necessary for, or reasonably useful to, METUCHEN to exercise any of METUCHEN’s
rights or perform any of METUCHEN’s obligations under this Agreement.

 

1.26             
“HYBRID Patent Rights” means any and all rights under any Patents owned or Controlled by HYBRID or its Affiliates in
any country of the Territory, as of the Effective Date or at any time until the Launch Date of the first Product that relate to or may
be useful to the development, manufacture, use, sale, offer for sale, distribution, importation, exportation or other exploitation of
the Product(s). HYBRID Patent Rights includes the patents and patent applications listed on Schedule 1.87 (HYBRID Patent Rights) and the
HYBRID Developed Patents.

 

1.27             
“HYBRID Technology” means: (a) the HYBRID Know-How, (b) the HYBRID Patent Rights; (d) HYBRID Work Product; (e) HYBRID
New Inventions; and (f) HYBRID New Patents.

 

 1.28              “HYBRID Work Product” means Work Product owned by HYBRID.

 

1.29             
“IND” means an Investigational New Drug Application, or the equivalent submission in any country, submitted to a Regulatory
Agency.

 

1.30             
“Ineligible Person” means a Person who: (a) is currently excluded, debarred, suspended, or otherwise ineligible to
participate in Federal health care programs or in Federal procurement or non-procurement programs; or (b) has been convicted of a criminal
offense that falls within the ambit of 42 U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared
ineligible.

 

1.31             
“Launch Date” means the date of the First Commercial Sale of a Product by or on behalf of METUCHEN, its Affiliates
or a sublicensee of METUCHEN to a Customer in the Territory.

 

1.32             
“Legal Requirements” means: (a) all applicable laws, statutes, rules, regulations, or ordinances of a Governmental
Authority; (b) Current Good Manufacturing Practices, Current Good Laboratory Practices, Current Good Clinical Practices, ICH guidelines
and all applicable regulations of the FDA and any other applicable regulatory authority;

 

     6

     

    

 

CONFIDENTIAL

 

1.33             
“Licensed Work Product” means (i) the METUCHEN Work Product and (ii) the data described in Section 3.4 (Regulatory
Submissions and Cooperation).

 

1.34
             “Marketing Approval” means the receipt of the applicable approvals, licenses, registrations or authorizations of any
federal, state or local Regulatory Agency, department, bureau or other governmental entity, necessary for the sale of a Product in a country
or region, but shall not include Price Approval in any country.

 

1.35
             “METUCHEN Royalty Period” means, on a country-by-country basis, the period commencing on the Launch Date for the applicable
Product in the applicable country and terminating upon the expiration of the last to expire issued patent within the HYBRID Patent Rights
or HYBRID New Patents having at least one Valid Claim covering Product Rights.

 

1.36              “METUCHEN Technology” means,
collectively: (a) METUCHEN Work Product; (b) METUCHEN Inventions; and (c) METUCHEN Developed Patents.

 

1.37              “METUCHEN
Trademark(s)” means any of the trademarks, service marks, logos, product configuration, trade dress or trade names used by
METUCHEN and/or developed by METUCHEN in connection with the Product(s) during the Term of this Agreement including any trademarks,
service marks, logos, product configuration, and/or trade dress for use with the Product(s).

 

 1.38              “METUCHEN Work Product” means Work
Product owned by METUCHEN.

 

1.39
             “NDA” means a New Drug Application, or the equivalent submission, submitted to the applicable Regulatory Agency.

 

1.40             
“Net Sales” means, for the applicable period, the gross amounts invoiced for sales of all applicable Products by METUCHEN,
its Affiliates or their respective sublicensees to Third Parties, less the Net Sales Adjustments, all in accordance with standard
allocation procedures, allowance methodologies and accounting methods consistently applied, which procedures and methodologies shall be
in accordance with GAAP. For the avoidance of doubt, the transfer of any Product by METUCHEN or one of its Affiliates to another Affiliate
of METUCHEN shall not be considered a sale; in such cases, Net Sales shall be determined based on the gross invoiced sales made by such
Affiliate to a Third Party, less the Net Sales Adjustments. Net Sales shall not include distribution to a Third Party of Products for
research, manufacturing or quality testing, clinical trials, compassionate or humanitarian purposes including expanded access programs
(which provide access to therapies for no monetary consideration) or charitable donations.

 

1.41             
“Net Sales Adjustments” means the following items as applicable to each such Product to the extent such items are customary
under industry practices:

 

(a)              
credits or allowances actually granted upon returns, rejections or recalls (due to spoilage, damage, expiration of useful life),
retroactive price reductions, or billing corrections;

 

(b)              
invoiced freight, postage, shipping, shipping insurance, handling and other transportation costs;

 

     7

     

    

 

CONFIDENTIAL

 

(c)              
credits or allowances actually granted including quantity, cash, bad debt and other trade discounts; and

 

(d)              
taxes (including sales, value-added or excise taxes, but excluding withholding taxes and taxes paid by METUCHEN on the net income
derived from sales of the Products), tariffs, customs duties, surcharges and other governmental charges incurred in connection with the
sale, transportation, delivery, exportation or importation of Products that are actually incurred at time of sale or are directly related
to the sale and not otherwise previously deducted.

 

1.42         
“Patent(s)” means any and all rights under any patents, patent applications and patents issuing on such patent applications,
together with any continuations, continuations-in-part, divisionals, reissues, renewals, reexamination certificates, substitutions, extensions,
supplementary protection certificates or certificates of invention with respect to any of the foregoing.

 

1.43         
“Person” means any natural person, corporation, partnership, trust, joint venture, Governmental Authority or other
entity or organization.

 

1.44         
“Price Approval” means, with respect to any country in which the price at which METUCHEN or its Affiliates or sublicensees
sells Product must be approved by a Governmental Authority or Regulatory Agency for reimbursement or payment purposes, the receipt of
approval by the applicable authority with respect to such price.

 

 1.45         
 “Product(s)” has the meaning provided in the Recitals.

 

1.46         
“Product Rights” means the applicable Product or its use, manufacture, offer for sale, sale or importation.

 

1.47         
“Promotional Activities” means the detailing of Product by sales representatives or other marketing means to promote
the applicable Product in accordance with the terms and conditions of this Agreement to a licensed health care professional.

 

1.48         
 “Regulatory Agency” means: (a) with respect to the United States, the FDA; and( b)   in
the case of a country other than the United States, such other appropriate regulatory agency or authority with similar
responsibilities.

 

 1.49         
 “Territory” means: the entire world.

 

1.50         
“Therapeutic Equivalent” has the meaning given to it by the FDA in the current edition of the “Approved Drug
Products with Therapeutic Equivalence Evaluations” (the “Orange Book”) as may be amended from time to time.

 

1.51          “Valid
Claim” means a claim in HYBRID Patent Rights that has not been: (a) canceled; (b) revoked or declared invalid and/or
unenforceable by an unreversed and unappealable or unreversed and unappealed decision of a court or other appropriate body of
competent jurisdiction; (c)  admitted to be invalid or
unenforceable through disclaimer, or surrendered during a reissue or reexamination; or (d) abandoned.

 

     8

     

    

 

CONFIDENTIAL

 

1.52         
“Work Product” means any and all technical, scientific, regulatory, clinical and medical information and data, know-how,
formulations, trade secrets, techniques, processes, ideas, concepts, designs, original works of authorship, enhancements, derivative works,
adaptations and discoveries developed, conceived, reduced to practice, originated, prepared, learned, generated, obtained or made by or
on behalf of a Party or its Affiliates and arising out of such Party’s performance (whether directly or through the use of a Party’s
Affiliates or Third Parties performing for such Party or its Affiliates) under this Agreement after the Effective Date, including all
formulations, manufacturing processes, preclinical and clinical data, analytical and quality control data, stability data, studies and
procedures and marketing studies as well as drug applications and interactions with regulatory authorities.

 

 2.             RIGHTS AND RESTRICTIONS.

 

 2.1          Grant of Licenses to METUCHEN.

 

(a)              
Subject to the terms and conditions of this Agreement (including payment of the royalties set forth in Section 4.3 (METUCHEN Royalty
Payments) and Section 6 (Term and Termination)), HYBRID hereby grants to METUCHEN, and METUCHEN hereby accepts, the following rights (collectively
referred to as the “METUCHEN Rights”): an exclusive (even as to HYBRID) right and license (with the right to transfer, sell,
or grant sublicenses) in, to and under the HYBRID Technology to research, have researched, make or have made, use or have used, improve
or have improved, develop or have developed, apply for regulatory approval, market or have marketed, distribute or have distributed, import
or have imported, export or have exported, practice, have practiced, sell, offer for sale, have sold or otherwise exploit Product(s) in
the Field in the Territory, including all intellectual property, future formulation development, clinical trial expenses and regulatory
fees.

 

METUCHEN will have exclusive operational
and budgetary oversight for all development, manufacturing, marketing, lifecycle strategy and commercialization efforts including all
regulatory applications and approvals.

 

Subject to Section 6 (Term and
Termination) and Section 4.3 (METUCHEN Royalty Payments), the licenses granted to METUCHEN under this Section 2 are irrevocable and perpetual,
subject to Section 6 (Term and Termination). In addition, upon expiration of the METUCHEN Royalty Period for a Product in a country, no
further royalties shall be payable in respect of sales of such Product in such country and thereafter the licenses granted to METUCHEN
under this Section 2 with respect to such Product in such country shall be fully paid-up and royalty-free, and METUCHEN shall have the
right to exploit, without any obligation of accounting or otherwise to HYBRID, the Products, in accordance with the licenses granted to
METUCHEN in this Section 2.

 

(b)               Subject
to Section 6 (Term and Termination) and Section 4.3 (METUCHEN Royalty Payments), HYBRID hereby grants to METUCHEN, and METUCHEN
hereby accepts, an exclusive (even as to HYBRID), royalty-free, irrevocable, perpetual right and license (with the right to
transfer, sell or otherwise grant sublicenses) to the HYBRID Technology, and all improvements thereof, or relating thereto.

 

     9

     

    

 

CONFIDENTIAL

 

2.2          Sublicenses.
In accordance with the license granted in Section 2.1 above, METUCHEN has the right to exercise some or all of the METUCHEN Rights through
one or more Affiliates, sublicensees or subcontractors, and to provide sublicenses thereto.

 

2.3          Formulation
Rights. HYBRID acknowledges the substantial investment in time, money and other resources that METUCHEN is making and will continue
to make with respect to development of Product under this Agreement. Accordingly: (a) HYBRID agrees that the HYBRID Know-How includes
any existing PRODUCT formulations (including improvements thereto) developed and owned by HYBRID as of the Effective Date, including
any future improvements thereto; (b) HYBRID and HYBRID shall disclose to METUCHEN promptly any existing or future PRODUCT formulations
(including improvements thereto) described in subsection (a) above; and (c) neither HYBRID nor any of its Affiliates shall, directly
or indirectly, utilize or license the HYBRID Technology for the purposes of researching, making, using, improving, developing, marketing,
commercializing, distributing, importing, selling, offering for sale, or otherwise exploiting in or for the Territory, nor shall HYBRID
nor any of its Affiliates, either directly or indirectly, utilize or license the HYBRID Technology to assist any Third Party in researching,
making, using, improving, developing, marketing, commercializing, distributing, importing, selling, offering for sale, or otherwise exploiting,
in or for the Territory, any PRODUCT, or that otherwise is for the same indication or competitive therewith. HYBRID acknowledges and
agrees that this Section 2.3 is binding upon HYBRID and any successor or assigns of HYBRID.

 

2.4           Option.
METUCHEN shall have the option (hereinafter “Option”) to any new indications for the Product developed by HYBRID.
METUCHEN will provide written notice to HYBRID of an Option at the HYBRID address specified in Section 12.5 (the “Option
Notice”). Such Option shall be kept open, and exercisable by METUCHEN up to and including the time of patent application for
the Product or indication, establishment or the development of data reasonably sufficient to provide a regulatory pathway for
approval of indication of use whichever of the foregoing is latest (“Option Period”). Any such exercise will operate to
include the Optioned product in the Product and in accordance with the terms of this Agreement. Exercise of such Option will be on
the basis of payment by METUCHEN of a fee of $250,000 per indication within thirty (30) days of the sending of the Option Notice to
HYBRID. If METUCHEN fails to make the required payment within the required time frame, METUCHEN is automatically and without further
action required deemed to have forever waived such Option. To the extent METUCHEN exercises its Option to additional products and/or
indications as contained herein, such Optioned product shall be subject to the License hereunder, and under the same Terms and
Conditions of this Section 2, along with any other commercial terms which may be reasonably agreed between the Parties and such
product shall be included as a Product and such indication shall be included within the Field.

 

2.5              No
Other Rights. Except as otherwise expressly provided in this Agreement, under no circumstances does a Party hereto, as a result
of this Agreement, obtain any ownership interest in or other right or license to any technology, regulatory submissions, or Patents
rights of the other Party, including items owned, Controlled or developed by the other Party, or transferred by the other Party to
said Party at any time pursuant to this Agreement.

 

     10

     

    

 

CONFIDENTIAL

 

2.6             
M&A Circumstance. If a third-party acquirer approaches METUCHEN for acquisition, H100 will be valued by the third party
acquirer as a component of due diligence and asset valuation (valuation process to be neutral, fair and diligent in assessment process).
In such event, HYBRID will receive 10% of Hl00 valuation accordingly as a transactional remuneration of the acquisition. Additionally,
under the scenario of acquisition, third party acquirer will be contractually obligated to accept as binding on it the conditions and
terms of this Agreement, rendering this Agreement durable through any further acquisition transaction, and abiding by the terms in this
Agreement.

 

3.            
RESPONSIBILITIES OF PARTIES.

 

 3.1               HYBRID Responsibilities.

 

HYBRID will
provide METUCHEN with any IND’s, or other regulatory information and/or clinical trial data previously conducted by it, or by any
other institution or investigator or consultant on its behalf. For the avoidance of doubt, the foregoing includes all reports and analyses
by HYBRID or its consultants with respect to the regulatory pathway or clinical trial or other investigation requirements which might
be required by the FDA or any other regulatory body including IRB’s, reports and data from any research and development, or investigations
conducted by HYBRID or any third party with regard to the Product or its active ingredients, including toxicological, animal and human
studies, notes, minutes and correspondence with the FDA, any presentation or meeting materials prepared by or on behalf of HYBRID.

 

		3.1.1	Technology Transfer.

 

(a)              
Beginning promptly after execution of this Agreement and continuing thereafter, HYBRID shall provide to METUCHEN competent and
knowledgeable assistance to facilitate the transfer of the HYBRID Technology to and for the use of, METUCHEN and its designees in accordance
with the terms of this Agreement. As an example, HYBRID shall cooperate with and provide METUCHEN, its Affiliates and Third Party contract
manufacturers with such reasonable assistance as HYBRID and METUCHEN jointly agree is reasonably necessary, with possible travel expense
remittance as necessary and appropriate for such collaboration.

 

(b)              
Unless otherwise stated herein, HYBRID shall deliver to METUCHEN, the documents and information comprising the complete technical
transfer package it has as of the Effective Date including any and all incomplete or draft reports, data and other documents relating
to any consultants, attorneys, physicians, scientists or governmental regulatory bodies including but not limited to the USFDA and USPTO.

 

3.1.2         Regulatory
Proceedings. Upon METUCHEN’s reasonable request, HYBRID shall cooperate with and provide METUCHEN all such assistance,
documentation and information as reasonably necessary or useful with respect to any of METUCHEN’s regulatory submissions or
proceedings in connection with the Product, including providing access to HYBRID Technology, applicable personnel, records,
materials, data, facilities or any other items reasonably requested by METUCHEN.

 

     11

     

    

 

 

CONFIDENTIAL

 

3.1.3       
Cooperation with Regulatory Agencies. HYBRID shall cooperate with METUCHEN and the applicable Governmental Authority or
Regulatory Agency with respect to any inspections it may require of HYBRID’s or its respective subcontractors’ facilities
and procedures relevant to and in connection with the Product(s). HYBRID shall promptly provide METUCHEN with written notice and, as applicable,
copies of any communications between HYBRID and the applicable agencies with respect to the HYBRID Technology, laboratory facilities or
the Product(s) to the extent such communications are relevant to the Product(s).

 

3.2          
Non-Compete/Exclusivity. In no event shall HYBRID or any affiliate of HYBRID, including but not limited to an acquirer in
whole or in part, or any joint venturer market any product in competition with the Product (including any Product covered by the Option
provision before or after exercise as described hereinabove). Competition includes any product marketed for the treatment of Peyronie’s
disease or any Product hereunder. This includes any license or permission to any other party to market, make or promote a Product, including
but not limited to compounding pharmacies. For the avoidance of doubt, HYBRID shall, no later than the date on which METUCHEN pays to
HYBRID the remaining Eight Hundred Thousand Dollars ($800,000.00) under Section 4.1.2 below or the remaining Nine Hundred Thousand Dollars
($900,000.00) under Section 4.1.3 below, as applicable, cease any sale, marketing or promotion directly or indirectly, or any license
or permission to any other party or compounding pharmacy to make, market, sell or distribute any Product. The foregoing shall not be construed
as limiting HYBRID from maintaining a corporate website which states only that a Product for its indication has been licensed to METUCHEN.

 

		3.3	METUCHEN Responsibilities

 

3.3.1       
METUCHEN, in good faith effort and procession of clinical development and commercialization, will expend sufficient and reasonable
effort towards sequential process of clinical development, reasonably accommodative of ordinary process hurdles or delays.

 

3.3.2       
Below is a proposed initial development roadmap intended to demonstrate the potential stepwise process correlated with reasonable
estimated periods. Reasonable commercial efforts will be made compliantly, diligently and effectively to commercialize product in as promptly
a timeline as process allows.

 

    12

     

    

 

CONFIDENTIAL

 

 

 

3.4          
Additional Responsibilities of METUCHEN. In addition to METUCHEN’s other responsibilities under this Agreement and
subject to the other terms and conditions of this Agreement, METUCHEN shall use commercially reasonable efforts to undertake the following
activities in the Territory with respect to the Product, which activities may in METUCHEN’s discretion be carried out by METUCHEN
alone, or together with an Affiliate or subcontractors:

 

(a)             
Conduct the appropriate clinical trials and toxicology studies and prepare and file the necessary regulatory submissions in order
to obtain Marketing Approval from the FDA;

 

(b)             
Work alone or together with its Affiliates and subcontractors to conduct formulation process development, scale-up and validation;

 

(c)             
Undertake development and regulatory filing of the Product in accordance with the Development Strategies Program, and which efforts
by METUCHEN shall be substantially similar to METUCHEN’s efforts for its own products of similar commercial potential taking into
account scientific, business, marketing and return on investment considerations, and taking into account that each of such considerations
may change over time; and

 

(d)             
Provide HYBRID with monthly updates during the first year, and quarterly thereafter, regarding METUCHEN’s progress with respect
to the Development Strategies Program, including providing summaries of scientific results, clinical trial results and material FDA meetings,
notices and approvals, all of which will be memorialized in minutes of such reports unless otherwise agreed by the Parties.

 

    13

     

    

 

CONFIDENTIAL

 

		3.5	Regulatory Submissions and Cooperation.

 

Subject to the terms of this Agreement, including
METUCHEN’s undertakings set forth in Section 3.3 above, METUCHEN, in its reasonable discretion, shall have the sole right to
submit any and all regulatory submissions within the Territory with respect to Product(s) developed under this Agreement In
addition, METUCHEN also shall have the right to list in the FDA’s Orange Book any HYBRID Patent Rights that cover the Product
or are directed to a method of treating INDICATION by administration of the Product. All such submissions will be the exclusive
property of METUCHEN.

 

3.6           Commercial
Launch.

 

Subject to the other terms and conditions
of this Agreement, METUCHEN shall undertake launch, sales and marketing of the Product in the Territory using efforts substantially similar
to METUCHEN’s commercialization efforts for its own products of similar commercial potential taking into account scientific, business,
marketing and return on investment considerations, and taking into account that each of such considerations may change over time.

 

4.            
PAYMENT TERMS. Subject to the terms and conditions of this Agreement, the Parties shall make the applicable payments in
accordance with the terms and conditions set forth below.

 

		4.1	License Fees. METUCHEN shall pay HYBRID license fees as follows:

 

4.1.1       
Upfront Payment. METUCHEN shall pay HYBRID the non-refundable, non-creditable amount of One Hundred Thousand Dollars ($100,000.00)
in consideration of the license herein, to be paid on the Effective Date.

 

4.1.2       
First Three Month Period. During the initial three (3) month period immediately following the Effective Date (the “Initial
Period”), if Metuchen receives: (i) confirmation from the FDA of Orphan Drug status for the Product for Peyronie’s Disease,
and (ii) written confirmation by HYBRID with acknowledgement by its counterpart contracting part(ies) of termination of any and all licenses,
permission, or other agreements involving the Products (which may occur through execution of an Amendment providing for a full and final
termination, without cause, on reasonable notice, of the agreement between Custom RX, LLC and HYBRID in a form mutually acceptable to
HYBRID and Metuchen), then Metuchen will pay to HYBRID the non-refundable, non-creditable amount of Nine Hundred Thousand Dollars ($900,000.00)
within seven (7) days after receipt of such confirmation. If Metuchen does not receive confirmation from the FDA of Orphan Drug status
for the Product for Peyronie’s Disease during the Initial Period, then METUCHEN will have the option to pay an additional non-refundable,
non-creditable amount of One Hundred Thousand Dollars ($100,000.00) within seven (7) days of the end of the Initial Period (the “Extension
Option Period”) to extend this Agreement for an additional three (3) months from the end of the Initial Period (the “Second
Period”). If Metuchen does not pay the additional One Hundred Thousand Dollars ($100,000.00) within the Extension Option Period,
then this Agreement is automatically terminated immediately with no further obligations due by either party to the other.

 

4.1.3         Second
Period. During the Second Period, if Metuchen receives: (i) confirmation from the FDA of Orphan Drug status for the Product for
Peyronie’s Disease, and (ii) written confirmation by HYBRID with acknowledgement by its counterpart contracting part(ies) of
termination of any and all licenses, permission, or other agreements involving the Products (which may occur through execution of an
Amendment providing for a full and final termination, without cause, on reasonable notice, of the agreement between Custom RX, LLC
and HYBRID in a form mutually acceptable to HYBRID and Metuchen), then Metuchen will pay to HYBRID the non-refundable,
non-creditable amount of Eight Hundred Thousand Dollars ($800,000.00) within seven (7) days after receipt of such confirmation. If
Metuchen does not receive confirmation from the FDA of Orphan Drug status for the Product for Peyronie’s Disease as of the end
of the Second Period, then Metuchen will have the right, exercisable for a period of seven (7) days thereafter, (the
 “Termination Period”) to terminate this Agreement immediately with no further obligations by either party to the other.
In the event that METUCHEN has not exercised its right of termination within the Termination Period, then METUCHEN will pay to
HYBRID the non-refundable, non-creditable amount of Eight Hundred Thousand Dollars ($800,000.00) within three (3) days after the end
of the Termination Period.

 

    14

     

    

 

CONFIDENTIAL

 

4.2       
Milestone Payments. In addition to the payments in Section 4.1, METUCHEN shall pay HYBRID the non-refundable, non-creditable
against future royalty, milestone payments in accordance with the terms and conditions as follows:

 

		4.2.1	First Anniversary of this agreement $125,000

 

		4.2.2	Second Anniversary of this agreement $150,000

 

		4.2.3	Third Anniversary of this agreement $200,000

 

		4.2.4	Fourth Anniversary of this agreement $250,000

 

		4.2.5	Fifth Anniversary and beyond of this agreement $250,000

 

		4.2.6	First Commercial Sale $1,000,000

 

		4.2.7	Cumulative Net Sales of $50M $2,500,000

 

		4.2.8	Cumulative Net Sales of $100M $4,000,000

 

		4.2.9	Cumulative Net Sales of $250M $7,500,000

 

		4.2.10	Cumulative Net Sales of $500M $10,000,000
	 	 	 
	 	4.2.11	Once the first commercial sale is executed, Anniversary milestones shall no longer be paid; only Net Sales payments will be made,
as incurred based on the foregoing.

 

    15

     

    

 

		4.3	METUCHEN Royalty Payments.

 

4.3.1       
METUCHEN Periodic Royalties. During the METUCHEN Royalty Period, METUCHEN shall pay HYBRID royalties in accordance with
this Section 4.3 (METUCHEN Royalty Payments).

 

(a)             
METUCHEN shall pay HYBRID a royalty in the amount of six percent (6%) of cumulative Net Sales in countries in the Territory where
a Product Right is covered by one or more Valid Claims of HYBRID Patent Rights or the HYBRID New Patents (“METUCHEN Royalty Payment”).

 

(b)              
Royalty Payment shall be paid beginning with the First Commercial Sale of the Product and continuing for METUCHEN Royalty Period.

 

(c)            
METUCHEN shall pay the METUCHEN Royalty Payment within forty-five (45) calendar days following the end of each calendar quarter.

 

(d)              
In the event a significant change in market conditions (drop in sales by at least 50% over six months due to, by way of example
and not limitation, regulatory changes or delays, Regulatory Agency action, recalls, interruption in supply, the introduction of a competing
or generic product in the Territory, changes in federal or state reimbursement programs, changes in the pricing of competing products,
etc.) has a material adverse effect on actual sales of the applicable Product, the parties will negotiate in good faith to revise the
Royalty Payment to reflect such changes by up to a 50% reduction in the royalty rate, in which case the calculation of the Royalty Payment
shall be adjusted to account for such changes. In the event a cumulative series of events occur, qualifying for a compounded reduction
of royalty rate, described within this section (4.3.1 (d)), the final royalty rate shall not be reduced beyond 50% from original schedule
stated within this agreement.

 

(1)             
If the Parties are unable to agree to adjustment of the Royalty within thirty (30) calendar days following METUCHEN’s receipt
of HYBRID’s written objections, the Parties shall refer the matter for resolution to an independent Third Party expert mutually
agreed to by the Parties, which expert shall have at least five (5) years of relevant experience in the area of specialty pharmaceutical
product sales (the “Arbiter”). The Arbiter shall review the applicable sales forecast (including the assumptions on which
it is based) and HYBRID’s objections thereto and render a decision, which decision (a) shall take into consideration the assumptions
made by METUCHEN with respect to the sales forecast, (b) shall be based on objective market criteria and conditions and (c) may include
adjustments to the Sales Forecast based on the findings of the Arbiter. Each Party shall have an opportunity to present their position
to the Arbiter and the Arbiter may determine the process for presenting each Party’s position. The decision of the Arbiter with
respect to the Sales Forecast shall be final and binding on both Parties.

 

(2)              
Each party shall be responsible for its costs and expenses of the Arbiter.

 

(e)               Notwithstanding
anything in this Agreement to the contrary, the Royalty obligations with respect to a Product shall apply only if a Product Right is
covered by one or more Valid Claims within the HYBRID Patent Rights for the applicable country and shall terminate on a country by
country basis for the applicable Product in the applicable country upon the expiration of the last to expire issued Patent within
the HYBRID Patent Rights having at least one Valid Claim covering one or more Product Rights.

 

    16

     

    

 

CONFIDENTIAL

 

4.4        
Reporting Obligations. The METUCHEN Royalty Payments shall be accompanied by a written report setting forth the Net Sales
of the Product(s) sold by METUCHEN during the applicable quarterly period and the calculation of royalties payable for each such quarterly
period.

 

4.5         
Records Audit. HYBRID shall have the right, at its sole cost and expense, through a certified public accountant reasonably
acceptable to the other METUCHEN (the “Accountant”), to examine the relevant records of METUCHEN during regular business hours
during the Term of this Agreement and for one (1) year thereafter to verify the calculation of royalty payments pursuant to Section 4.3
(METUCHEN Royalty Payments) (the “Records”); provided, however that such examination shall not occur more often
than once per year and shall not include any Records prior to the three (3) years preceding the accounting. HYBRID shall bear the expense
of any such audit unless the audit reveals an underpayment of the applicable royalty payments to HYBRID which in the aggregate require
payment to HYBRID in an amount equal to five percent (5%) or more of the total amount due for any calendar year, in which case METUCHEN
shall bear the expense of such audit. In the event any errors in payment are discovered by the audit, the Party in error shall pay such
amounts due within ten (10) business days following receipt of a demand for payment from the aggrieved Party. If payment will not be made,
the Party in error, must, within the same time period as specified for payment, advise the aggrieved Party in written detail of its objections
to the audit conclusion. If no agreement can be reached with respect to the amount in dispute, the dispute shall be handled in accordance
with the dispute resolution procedures set forth in Section 11 (Dispute Resolution).

 

		4.6	Taxes.

 

(a)               Each
Party (the "Paying Party") shall pay all taxes and levies that by applicable Legal Requirements (including existing
treaties for bilateral taxation) such Paying Party is required to pay on payments accruing under this Agreement and shall withhold
from sums payable to the other Party all such taxes and levies and the Paying Party shall forward to the other Party documentation
evidencing such payments whenever possible. To the extent that the Paying Party determines that it is required to withhold any taxes
or levies on payments to the other Party, the Paying Party shall provide the other Party with reasonable prior written notice of the
Paying Party's determination in order to provide the other Party an opportunity to provide comments regarding the Paying Party's
decision to withhold, which comments the Paying Party shall consider in good faith. To the extent that the Paying Party withholds
any taxes or levies on payments to the other Party, such other Party agrees that the Paying Party shall not be obligated to gross-up
any such amounts and the other Party waives any right to payment from the Paying Party with respect to the withheld amounts which
the Paying Party actually paid to the relevant Governmental Authority pursuant to such applicable Legal Requirements provided the
Paying Party provides sufficient documentation from such relevant Governmental Authority evidencing payment. However, if the Paying
Party receives a refund of any taxes or levies withheld from amounts paid to the other Party under this Agreement, the Paying Party
shall pay to the other Party an amount equal to such refund, provided that the other Party upon request of the Paying Party, agrees
to repay the amount paid over to other Party (plus any penalties, interest, or other charges imposed by the relevant Governmental
Authority) by the Paying Party, if the Paying Party is required to repay such refund to such Governmental Authority. The Paying
Party shall promptly notify the other Party of any notifications and discussions with any Governmental Authorities regarding any
such refund.

 

    17

     

    

 

CONFIDENTIAL

 

(b)              
The Parties will cooperate with respect to tax matters relating to this Agreement including by providing an IRS Form W-9 or IRS
Form W-8BEN (or other such form demonstrating an exemption from applicable taxes or levies as may be reasonably requested by the other
Party), provided that such Party is legally entitled to do so. If any IRS Form expires or becomes obsolete or inaccurate in any respect,
the Party that provided such form shall promptly (and in any event within thirty (30) days after such expiration, obsolescence, or inaccuracy)
notify the other Party in writing of such expiration, obsolescence, or inaccuracy and update the IRS Form if it is legally eligible to
do so.

 

(c)              
In the event that any taxes or levies are assessed against one Party (the “Assessed Party”) with respect to payments
made by the Assessed Party to the other Party (the “Non-Assessed Party”) under this Agreement, such taxes or levies (plus
any penalties, interest, or other charges imposed by the relevant Governmental Authority not related to any delinquency of payment once
the taxes have been assessed) shall be paid by the Non-Assessed Party. Should the Assessed Party have to pay such taxes or levies, the
Non-Assessed Party shall promptly reimburse the Assessed Party in full for any taxes or levies (plus any penalties, interest, or other
charges imposed by the relevant Governmental Authority not related to any delinquency in payment once the taxes have been assessed) so
paid by the Assessed Party upon receipt of a copy of the assessment. Alternatively, the Assessed Party may reduce the amount of future
payments to the Non-Assessed Party under this Agreement so as to recover in full any such taxes or levies (plus any penalties, interest,
or other charges imposed by the relevant Governmental Authority not related to any delinquency in payment once the taxes have been assessed)
so paid by the Assessed Party.

 

4.7          
Currency. All payments to be paid to each Party hereunder shall be computed and made in United States Dollars.

 

		5.	REPRESENTATIONS, WARRANTIES AND COVENANTS.

 

5.1          
Representations, Warranties and Covenants of Each Party. Each of the Parties represents, warrants and covenants to the other
that:

 

(a)              
it is validly existing and in good standing under the Legal Requirements of the jurisdiction of its incorporation;

 

    18

     

    

 

CONFIDENTIAL

 

(b)           
the execution of this Agreement and full and timely performance of the covenants, duties and obligations described herein have
been duly authorized by all necessary corporate action in accordance with all Legal Requirements;

 

(c)           
it has obtained, and will maintain during the Term, all applicable regulatory approvals, applications, licenses, requests for exemption,
permits or other regulatory authorizations with the applicable Regulatory Agency, or any state or local regulatory body necessary to conduct
its business activities to date and to conduct its activities under the Agreement on and following the Effective Date;

 

(d)           
it has the full power and authority to execute and deliver this Agreement and perform its covenants, duties and obligations described
in this Agreement;

 

(e)           
this Agreement is a valid, legal and binding obligation upon such Party, enforceable in accordance with its terms, except as enforceability
may be limited by applicable insolvency and other Legal Requirements affecting creditors’ rights generally or by the availability
of equitable remedies;

 

(f)            
all work performed by or on behalf of a Party with respect to each Product will be conducted in material compliance with all applicable
Legal Requirements;

 

(g)           
neither it nor any of its personnel (including subcontractors) have been nor are disqualified or debarred under Section 306 of
the Federal Food, Drug and Cosmetic Act (as amended by the Generic Drug Enforcement Act of 1992), 21 U.S.C.

§ 336;

 

(h)           
it shall not use in any capacity the services of any Person who is debarred, disqualified or under investigation under the provisions
of the Section 306 of the Federal Food, Drug and Cosmetic Act (as amended by the Generic Drug Enforcement Act of 1992), 21 U.S.C. §
336, and will notify the other Party immediately in the event the Party is made aware of any investigation or proceeding for debarment;

 

(i)            
neither it nor any personnel within five (5) years preceding the Effective Date have been convicted of any offense required to
be listed under FDA regulations; and

 

(j)           
it shall not use any Ineligible Person or a Person on an Exclusion List in connection with the performance of any of its obligations
or activities under the Agreement.

 

5.2          
Representations, Warranties and Covenants of HYBRID. HYBRID represents, warrants and covenants to METUCHEN that:

 

(a)           
HYBRID is the sole and exclusive owner of the HYBRID Technology in the Field in the Territory;

 

    19

     

    

 

CONFIDENTIAL

 

(b)              
HYBRID has the right, power and authority to grant to METUCHEN the licenses set forth in this Agreement, free and clear of any
liens, security interests, restrictions on use or encumbrances of any nature whatsoever;

 

(c)             
HYBRID has not specifically admitted and does not know of any verdict or decision holding that any claim of the HYBRID Technology
is invalid or unenforceable;

 

(d)              
HYBRID has maintained the HYBRID Patent Rights in full force and effect, including the payment of maintenance fees;

 

(e)               
HYBRID has not granted, and shall not grant to any Third Party or any Affiliate, any rights or licenses with respect to, or has
not otherwise taken any action that conflicts with, or adversely affects, the rights and licenses granted to METUCHEN under this Agreement;

 

(f)               
HYBRID represents and warrants that is has not had any communications, directly or indirectly, with the FDA or any other regulatory
agencies, or consultants or attorneys, with regard to the Product or the matters covered by this Agreement, including meetings, phone
calls, correspondence.

 

(g)              
the HYBRID Technology is not involved in nor, to the best of its knowledge, after due inquiry, has not been threatened by any third
party to be brought into, any court proceeding, arbitration, mediation interference, reissue, re- examination or opposition; there are
no allegations, claims, judgments or settlements, either actual or, to the best of its knowledge, after due inquiry, threatened, relating
to any of the Product(s) or the HYBRID Technology;

 

(h)             
there is no action, suit, claim, investigation or proceeding pending, or to the best of its knowledge, after due inquiry, threatened
against, by or affecting HYBRID, which, if adversely decided, might adversely affect: (1) HYBRID’s ability to enter into this Agreement;
(2) METUCHEN’s rights under this Agreement; or (3) HYBRID’s performance of its obligations under this Agreement;

 

(i)               
to the best of HYBRID’s knowledge, after due inquiry, HYBRID has licensed and provided to METUCHEN all of the rights owned
or Controlled by HYBRID as of the Effective Date reasonably necessary for METUCHEN to research, develop or have developed, make or have
made, use or have used, improve or have improved, market or have marketed, distribute or have distributed, import or have imported, practice,
have practiced, sell, offer for sale, have sold or otherwise dispose of the Product(s) in the Field in the Territory;

 

(j)               
HYBRID has not applied for, nor received, any funds or other benefits from governmental, quasi-governmental or other non-profit
sources that grant any such sources rights in or to the technology, intellectual property or know-how licensed hereunder or adversely
affect or otherwise restrict the rights granted to METUCHEN under this Agreement.

 

    20

     

    

 

CONFIDENTIAL

 

		5.3	METUCHEN Covenants. METUCHEN covenants to HYBRID that:

 

(a)              
neither METUCHEN nor any of its Affiliates will employ or knowingly use the services of any Person who is debarred or disqualified
under United States law, including 21 U.S.C. §335a, or any foreign equivalent thereof, in connection with activities relating to
any Products; and in the event that METUCHEN becomes aware of the debarment or disqualification or threatened debarment or threatened
disqualification of any Person providing services to METUCHEN or any of its Affiliates with respect to any activities relating to any
Products, METUCHEN will immediately notify METUCHEN in writing and METUCHEN will cease, or cause its Affiliate to cease (as applicable),
employing, contracting with, or retaining any such Person to perform any services relating to any Products;

 

(b)            
neither METUCHEN nor any of its Affiliates will, in connection with the exercise of METUCHEN’s rights or performance of its
obligations under this Agreement, directly or indirectly through Third Parties, pay, promise or offer to pay, or authorize the payment
of, any money or give any promise or offer to give, or authorize the giving of anything of value to a public official or entity or other
Person for purpose of obtaining or retaining business for or with, or directing business to, any Person, including METUCHEN and its Affiliates,
nor will METUCHEN or any of its Affiliates directly or indirectly promise, offer or provide any corrupt payment, gratuity, emolument,
bribe, kickback, illicit gift or hospitality or other illegal or unethical benefit to a public official or entity or any other Person
in connection with the exercise of METUCHEN’s rights or performance of METUCHEN’s obligations under this Agreement;

 

(c)              
neither METUCHEN nor any of its Affiliates (or any of their respective employees and contractors), in connection with the exercise
of METUCHEN’s rights or performance of METUCHEN’s obligations under this Agreement, shall knowingly cause HYBRID to be in
violation of Anti-Corruption Laws or Export Control Laws; and

 

(d)             
METUCHEN shall immediately notify HYBRID if METUCHEN has any information or suspicion that there may be a violation of Anti-Corruption
Laws or Export Control Laws in connection with the exercise of METUCHEN’s rights or performance of METUCHEN’s obligations
under this Agreement or any other Transaction Agreement.

 

5.4         
The Parties will cooperate with respect to tax matters relating to this Agreement including by providing an IRS Form W-9 or IRS
Form W-8BEN (or such other form demonstrating an exemption from applicable withholding tax as may be reasonably requested by the other
Party), provided that such Party is legally entitled to do so.

 

    21

     

    

 

CONFIDENTIAL

 

		6.	TERM AND TERMINATION.

 

6.1          
Term. The term of this Agreement shall commence on the Effective Date and unless earlier terminated pursuant to the terms
and conditions of this Section 6 (Term and Termination), shall expire upon the expiry of the METUCHEN Royalty Period (the “Term”).

 

6.2          
Termination for Default. Upon the occurrence and during the continuation of any Event of Default, the non-defaulting Party
shall have the right to terminate the Term of this Agreement in whole and pursue any other remedies provided under this Agreement or available
at law or in equity, by providing the defaulting Party with a prior written notice specifying the basis of the default (a “Notice
of Default”). An event of default under this Agreement shall be deemed to exist upon the occurrence of any one or more of the following
events (the “Event(s) of Default”):

 

(a)             
the material breach or inaccuracy of any of the representations, warranties or covenants of HYBRID set forth in this Agreement,
which breach or inaccuracy continues for a period ninety (90) calendar days after HYBRID’s receipt of METUCHEN’s Notice of
Default;

 

(b)            
the material breach or inaccuracy of any representations, warranties or covenants of METUCHEN set forth in this Agreement, which
breach or inaccuracy continues for a period ninety (90) calendar days after METUCHEN’s receipt of HYBRID’s Notice of Default;

 

(c)              
failure of METUCHEN to pay any undisputed amount due to HYBRID under this Agreement, which failure continues for a period of thirty
(30) calendar days after METUCHEN’s receipt of HYBRID’s Notice of Default; or

 

(d)               failure
of a Party to perform or comply with any other material obligation under this Agreement, including stagnation or cessation of
commercial or development activities, provided that such failure is not cured within one hundred twenty (120) calendar days
following the defaulting Party’s receipt of the Notice of Default from the non-defaulting Party (“Cure Period”),
such Cure Period to be extendable for an additional thirty (30) days upon the payment of an extension fee of $25,000 by the curing
party to the other party.

 

6.3        
Termination for Convenience. In addition to the termination option my METUCHEN in Section 4 hereinabove, METUCHEN may terminate
at any time after first anniversary without cause upon ninety (90) days' notice.

 

6.4         
Termination for Reasons of Safety. METUCHEN may terminate at any time with notice following the withdrawal of Product from
any market as a result of bona fide concerns based on specific and verifiable information that the Product is unsafe for administration
to humans.

 

		6.5	Effect of Termination or Expiration.

 

6.5.1        Effect
of Expiration of METUCHEN Royalty Period or Term of Agreement. Upon expiration of the applicable METUCHEN Royalty Period of a
Product or upon expiration of the Term of this Agreement, whichever occurs earlier METUCHEN shall have a fully paid-up, perpetual,
exclusive license to use the HYBRID Technology (including, without limitation, sale, transfer or license to third parties) for the
applicable Product(s) in the Field in the Territory including but not limited to all approved drug applications of any regulatory
authority.

 

    22

     

    

 

CONFIDENTIAL

 

6.5.2       
Termination by HYBRID for Default. Upon termination of this Agreement by HYBRID pursuant to Section 6.2 (Termination for
Default), the following shall occur:

 

(a)              
except as necessary for METUCHEN to perform the activities set forth below), METUCHEN shall, at HYBRID's written request assign
and transfer to HYBRID, all of METUCHEN's right, title, and interest in and to all regulatory filings, regulatory approvals, clinical
trial agreements, and other data relating to the use, sale, offer for sale or importation of the Product in the Field in the Territory.
Licensor shall pay Licensee for such transfer a fee equal to 50% of Licensee's documented costs to procure, register and maintain such
filings, approvals agreements and other data;

 

(b)            
the rights and licenses of METUCHEN’s sublicensees shall survive, provided that that such sublicensee agrees in writing that
(i) HYBRID is entitled to enforce all relevant provisions directly against such sublicense and (ii) HYBRID shall not assume, and shall
not be responsible to such sublicensee for, any representations, warranties or obligations of METUCHEN to such sublicensee, other than
to permit such sublicensee to exercise any rights to Products that are sublicensed under such sublicense agreement.

 

		6.5.3	Termination By METUCHEN for Default, Convenience.

 

(a)              
Upon termination of this Agreement by METUCHEN pursuant to Section 6.2 (Termination for Default), in addition to the other rights
and obligations of the Parties pursuant to Section 6, to the following shall occur:

 

		a)	the licenses granted to METUCHEN under Section

2.1 (Grant of Licenses to METUCHEN)
shall become fully-paid up and shall continue until terminated for a subsequent Event of Default pursuant to Section 6.2 (Termination
for Default) (provided that in no event will HYBRID be required to provide a refund for any prior amounts paid); and

 

b)           
other than the METUCHEN Royalty Payments or other payments due to be paid to HYBRID below, METUCHEN shall have no other payment
obligations upon its termination of this Agreement provided, however, the foregoing shall not be construed to limit the right of HYBRID
to recover damages from METUCHEN subject to the terms and conditions of this Agreement.

 

(b)            
Upon termination of this Agreement by METUCHEN pursuant to Section 6.3 “Termination for Convenience,” the following
shall occur:

 

METUCHEN shall, at
HYBRID's written request assign and transfer to HYBRID, all of METUCHEN's right, title, and interest in and to all regulatory
filings, regulatory approvals, clinical trial agreements, and other data relating to the use, sale, offer for sale or importation of
the Product in the Field in the Territory. HYBRID shall pay METUCHEN for such transfer a fee equal to 50% of METUCHEN's documented
costs to procure, register and maintain such filings, approvals agreements and other data.

 

    23

     

    

 

 

CONFIDENTIAL

 

6.5.4       
Additional Rights and Obligations of METUCHEN and HYBRID upon Termination or Expiration of the Agreement.

 

Upon termination or expiration of the Term of the Agreement
for any reason, the following provisions shall apply:

 

(1)              
Each Party shall return to the other Party or, as otherwise instructed, destroy the Confidential Information of the other Party
in its possession except (a) for that Confidential Information necessary for a Party to exercise any of its rights under this Section
6.5 (Effect of Termination or Expiration), (b) that the legal department of the receiving Party and its outside counsel (if any) each
may retain one copy of the Confidential Information received by the receiving Party, (c) for any Confidential Information contained on
electronic media for archival or backup purposes, provided that such Confidential Information may not be used for any purpose other than
a use permitted in this Agreement that extends beyond termination or expiration of the Agreement or for defending or enforcing any rights
in connection with this Agreement, and (d) as otherwise provided herein. Each Party shall certify completion of the foregoing in writing
within thirty (30) days of the expiration or termination of the Agreement. Notwithstanding the foregoing, return or destruction of Confidential
Information does not abrogate the continuing obligations of the receiving Party under this Agreement.

 

(2)              
Except as otherwise provided herein, each Party shall pay to the other any outstanding and undisputed amounts due and payable pursuant
to this Agreement, including (a) any METUCHEN Royalty Payments that are due and payable from METUCHEN to HYBRID, and if a milestone payment
has been earned in accordance with Schedule 4 (Payments) prior to the date that notice of termination has been sent to HYBRID, then METUCHEN
shall be obligated to pay such milestone payment in accordance with Schedule 4 (Payments) unless the termination is due to a material
breach of HYBRID. For clarity, unless the termination is due to a material breach of HYBRID if the milestone payment has been earned as
described above and the notice is sent during the forty-five (45) day payment period, the milestone payment will continue to be due from
METUCHEN to HYBRID.

 

    24 

     

    

 

CONFIDENTIAL

 

6.5.5        Survival.
Notwithstanding anything contained herein to the contrary the following Sections of the Agreement shall survive the expiration or
termination of the Term of this Agreement for any reason: Section 1 (Definitions) with respect to those defined terms in those
provisions of the Agreement that survive; Section 4 (Payment Terms) with respect to any payment obligations that continue for any
licenses that continue in accordance with the terms and conditions of this Agreement; Section 6.2 (Termination for Default) with
respect to any licenses or other rights or obligations of the Parties that survive the Term of the Agreement, it being acknowledged
by the Parties that any continuing licenses may be terminated in accordance with Section 6.2 (Termination for Default), in which
case the Parties will have the applicable rights afforded to a Party upon termination for an Event of Default; Section 7 (Ownership
and Other Proprietary Rights) only as the applicable terms and conditions apply to any licenses that continue; Section 8
(Confidentiality) subject to the scope of the licenses that may continue; Section 9.1 (Indemnification by HYBRID); Section 9.2
(Indemnification by METUCHEN); Section 9.3 (Procedures for Indemnification); Section 10 (Limitation on Liability); Section 11
(Dispute Resolution); Section 12 (Miscellaneous).

 

6.5.6       
In the event of an alleged breach of this Agreement, the prevailing Party shall be entitled to reimbursement of all of its costs
and expenses, including reasonable attorneys’ fees, incurred in connection with such dispute, claim or litigation, including any
appeal therefrom. For purposes of this Section, the determination of which Party is to be considered the prevailing party shall be decided
by the court of competent jurisdiction or independent party (i.e., mediator or arbitrator) that resolves such dispute, claim or
litigation.

 

		7.	OWNERSHIP AND OTHER PROPRIETARY RIGHTS.

 

7.1             
HYBRID Technology. Subject to the license, ownership and other rights, provided to METUCHEN herein including METUCHEN Technology
rights as defined in this Section 7, HYBRID retains all right, title and interest in the HYBRID Technology.

 

7.2             
METUCHEN Technology. METUCHEN owns all right, title and interest in and to the METUCHEN Technology. .

 

		7.3	Rights in Work Product.

 

		7.3.1	METUCHEN Rights.

 

(a)              
METUCHEN owns all right, title and interest in any and all information and intellectual property in the Metuchen Work Product.

 

(b)              
HYBRID shall not have any rights to the METUCHEN Work Product. HYBRID agrees not to knowingly, and not to knowingly assist Third
Parties to, apply to register or register title to any intellectual property rights in the METUCHEN Work Product including the METUCHEN
Developed Patents, the Licensed Work Product and the Developed Data.

 

		7.3.2	HYBRID Rights.

 

(a)              
HYBRID shall own all right, title and interest to any and all Work Product, including any and all intellectual property rights
arising therefrom, with the exception of the METUCHEN Work Product (collectively, “HYBRID Work Product”).

 

    25 

     

    

 

CONFIDENTIAL

 

(b)               Subject
to the rights to METUCHEN under this Section 7, METUCHEN shall not have any rights to the HYBRID Work Product except pursuant to:
(a) and to the extent of the licenses granted to METUCHEN hereunder, (b) the Option granted to METUCHEN hereunder or (c) a separate
written agreement to be negotiated between the Parties, which agreement would include commercial terms for the use of such other
HYBRID Work Product by METUCHEN. All other rights to HYBRID Work Product not expressly granted to METUCHEN under this Agreement are
reserved solely and exclusively to HYBRID.

 

		7.4	Inventions.

 

7.4.1       
Any HYBRID New Inventions and HYBRID New Patents shall (a) be considered part of the License for purposes of this Agreement, (b)
automatically become subject to the exclusive license grant under Section 2.1 (Grant of Licenses to METUCHEN) without further act of either
Party, and (c) be subject to all of the other applicable restrictions, terms and conditions set forth in this Agreement.

 

7.4.2       
METUCHEN Inventions. METUCHEN shall own all right, title and interest to (a) any inventions conceived or reduced to practice
by METUCHEN arising out of or relating to the METUCHEN Work Product (collectively, “METUCHEN Inventions”) and

(b) any Patents arising therefrom (“METUCHEN
Developed Patents”).

 

		7.4.3	Disclosure and Cooperation.

 

(a)              
Each Party covenants to promptly and fully disclose to the other Party in writing each invention owned by the other Party that
such Party conceives or reduces to practice under this Agreement. Such disclosure shall be made promptly, but in no event no later than
any of the following: thirty (30) days prior to the filing of a patent application, or ninety (90) days prior to a public disclosure,
or within 45 days of identification of a new invention as contained in company records.

 

(b)               A
Party that creates an invention subject to a license or assignment under this Agreement (an “Inventing Party”), on
behalf of itself and all Affiliates or applicable Third Parties, shall: (1) promptly disclose to the other Party any invention
conceived by the Inventing Party that the other Party owns pursuant to the terms and conditions of Section 7.4 (Inventions); and (2)
cooperate with the other Party to provide all assistance to and execute all documents reasonably required by such other Party to
establish, assign, perfect, protect enforce and affirm any and all of such other Party’s rights with respect to the applicable
invention. If the other Party, at any time, is unable for any reason to secure the signature of the Inventing Party, its Affiliates
or applicable Third Parties (as the case may be) to any document required to file, prosecute, register or memorialize the assignment
of any rights as set forth in the Agreement, the Inventing Party hereby irrevocably designates and appoints such other Party and
such other Party’s duly authorized officers and agents as the Inventing Party’s agents and attorneys-in-fact to act for
and on the Inventing Party’s behalf and instead of the Inventing Party to take all lawfully permitted acts to further the
filing, prosecution, registration, memorializing of assignment, issuance and enforcement of such rights, all with the same legal
force and effect as if executed by the Inventing Party. The foregoing is deemed a power coupled with an interest and is irrevocable
at all times.

 

    26 

     

    

 

CONFIDENTIAL

 

7.5             
Government Applications and Other Information. Any IND, NDA, abbreviated NDA (“ANDA”) or Scale Up and Post Approval
Changes (“SUPAC”) and any applications for Marketing Approval, Price Approval or any other approval from a Governmental Authority
or Regulatory Agency, and any information directly related thereto including communications with the applicable Regulatory Agency together
with the information and data contained therein shall be owned by METUCHEN or its Affiliates and shall be treated as METUCHEN Confidential
Information in accordance with Section 8 (Confidentiality) of this Agreement.

 

7.6             
Trademarks. All rights to and ownership of the METUCHEN Trademarks shall remain with METUCHEN, including any good will associated
therewith. All rights to and ownership of the HYBRID Trademarks shall remain with HYBRID, including any good will associated therewith,
METUCHEN shall have the sole right to market the Products under its own trade names and trademarks or those licensed by METUCHEN, subject
to the terms and conditions contained in this Agreement, including the license provisions contained in Section 2.1 (Grant of Licenses
to METUCHEN). METUCHEN also shall have the right to authorize one or more Third Parties to market Product(s) under the trade name, trademark
or brands of one or more Third Parties, subject to the terms and conditions contained in this Agreement, including the license provisions
contained in Section 2.1 (Grant of Licenses to METUCHEN). HYBRID shall have no rights to use METUCHEN Trademarks and shall restrict its
sublicensees from using METUCHEN Trademarks.

 

7.7             
Patent Marking. Both Parties shall mark any products, including the Products, sold or distributed pursuant to this Agreement
in accordance with the applicable patent statutes or regulations in the country or countries of sale thereof.

 

7.8             
Cooperation of Third Parties. Each Party represents and agrees that all of its employees and all of its Affiliates’
employees acting under its or its Affiliates’ authority under this Agreement shall be obligated under a binding written agreement,
relevant law, or established corporate policy to assign to the other Party such other Party’s rights as set forth in this Agreement.
In the case of all others acting in the performance of a Development Plan and Development Strategies Program on behalf of either Party,
such as consultants, subcontractors, licensees, sublicensees, outside contractors, clinical investigators, agents, or non-employees working
for non- profit academic institutions, such others also shall be obligated under an agreement that meets the criteria of the preceding
sentence, unless otherwise approved in writing by the other Party. Each Party agrees to undertake to enforce the agreements referenced
in this Section (including, where appropriate, by legal action).

 

7.9             
No Encumbrances. Except as expressly provided in this Agreement, HYBRID shall not sell, transfer, assign, mortgage, pledge,
lease, grant a security interest in (e.g., as collateral for a loan or other financing) or otherwise encumber any HYBRID Technology necessary
for the research, development, manufacture or commercialization of the Product in the Field in the Territory without the prior written
consent of METUCHEN.

 

    27 

     

    

 

CONFIDENTIAL 

 

		7.10	Registration and Maintenance of Intellectual Property.

 

		7.10.1	Prosecution.

 

(a)              
METUCHEN shall make commercially reasonable efforts to be responsible for any and all legal proceedings surrounding the development,
commercialization and sale of the Product within the Territory, at METUCHEN's sole expense. The foregoing includes, without limitation,
patent post-grant proceedings/oppositions, patent litigation (both enforcement and defense) including Paragraph IV litigation and product
liability litigation with the exception of product already sold or marketed by HYBRID or by its representative or licensee. HYBRID shall
reasonably cooperate with METUCHEN in such endeavors in circumstances where the participation of HYBRID as the patent holder of licensed
patent rights is necessary or useful at no additional cost, except for reimbursed expense for travel and lodging.

 

(b)              
Subject to the terms and conditions of this Agreement, METUCHEN undertakes to use commercially reasonable efforts in preparing,
filing and prosecuting, and shall control and be responsible for preparing, filing, prosecuting and maintaining, all Patents relating
to the Product, provided that METUCHEN shall cover expenses related thereto incurred with respect to such activities inside the Territory.
HYBRID shall promptly cooperate with any reasonable request from METUCHEN to: (i) add PRODUCT-related disclosures to HYBRID Patent Rights
in the Territory; and (ii) file any new patent application(s) related to PRODUCT or formulations or uses thereof that capture any previously
undisclosed subject matter that may support any claim directed to the composition or formulation of the Product or a method of treating
INDICATION by administration of the Product.

 

(c)              
During the Term, without the prior written consent of METUCHEN, HYBRID shall not: (1) cancel, revoke or withdraw; (2) admit to
be invalid or unenforceable through disclaimer, or surrender during a reissue or reexamination; (3) abandon, the HYBRID Patent Rights;
or (4) (A) disclaim the term of any issued US patents licensed to METUCHEN hereunder that include at least one claim directed solely to
the composition or formulation of the Product or a method of treating INDICATION by administration of the Product

 

7.10.2       
METUCHEN March-In Rights. If HYBRID decides not to: (a) prosecute HYBRID Patent Rights; (b) pay a maintenance fee and/or
annuities for any HYBRID Patents Rights in the Territory; or (c) take any other action necessary for the continued existence of the HYBRID
Patents Rights in the Territory, HYBRID shall promptly notify METUCHEN in writing; provided, however, to the extent reasonably practicable
under the circumstances, HYBRID shall use commercially reasonable efforts to provide such notice not less than thirty (30) calendar days
prior to a non-extendable response or deadline is due before the United States Patent and Trademark Office or other analogous agency anywhere
within the Territory. Within thirty (30) calendar days of receipt of such notice, METUCHEN shall have the right, in its sole discretion,
to take an assignment of such HYBRID Patents Rights in the Territory (such HYBRID Technology thereafter becoming METUCHEN Technology)
(collectively a “HYBRID Assignment”).

    28 

     

    

 

CONFIDENTAL 

 

		7.10.3	Assignment.

 

(a)              
In the event of a HYBRID Assignment pursuant to Section 7.10.2 (METUCHEN March In Rights), the Parties acknowledge and agree any
Assigned Materials shall be removed from the HYBRID Patents as of the date of a HYBRID Assignment.

 

(b)              
Any items identified in or covered by the HYBRID Assignment shall be referred to as the “Assigned Materials”) (as appropriate).
Upon the request of the non-assigning Party, the assigning Party shall execute: (1) any appropriate documentation necessary to assign,
cede and grant to the non-assigning Party all right, title, interest and possession in, to and under the Assigned Materials; and (2) any
instruments to maintain, register, renew, defend, enforce and/or assign any and all Patents, service marks, trademarks, trade dress, product
configuration, trade secrets, copyrights and/or any other intellectual property rights in relation to, associated with and/or arising
from the Assigned Materials. Notwithstanding the foregoing, each Party represents and warrants that, as applicable, it shall not contest,
deny or take any action inconsistent with the other Party’s ownership in or validity of the Assigned Materials pursuant to this
Section 7.10 (Registration and Maintenance of Intellectual Property).

 

		7.11	Enforcement.

 

7.11.1   
Notification. Each Party acknowledges and agrees that it shall notify the other Party in writing of any known or suspected
Third Party activity that may (a) infringe the HYBRID Patent Rights (the “Infringing Activity”), or (b) otherwise affect or
interfere with the licenses granted to such HYBRID Patent Rights under this Agreement, which notice shall include a reasonably detailed
and complete description of the Infringing Activity as is known by such Party. Notwithstanding the foregoing, the notifying Party shall
not be obligated to provide to the other Party any of its attorney-client privileged material or any information that the notifying Party
is prohibited to disclose pursuant to an agreement between the notifying Party and a Third Party.

 

		7.11.2	Right to Institute Action Regarding Infringing Activity.

 

(a)              
If the Infringing Activity infringes any of the following in the Territory: (1) a METUCHEN Developed Patent, or (2) a patent under
which HYBRID has any HYBRID Patent Right or that is a HYBRID Developed Patent and which same patent includes a claim that is directed
solely to the composition or formulation of the Product or a method
of treating that falls within the Field by administration of the Product, then METUCHEN shall have the first right, at its sole cost and
expense, to commence any Action against such Infringing Activity and only to the extent of the scope of the licenses granted to METUCHEN
under subsection (a)(i) of Section 2.1 (Grant of Licenses to METUCHEN).

 

(b)               If
the Infringing Activity infringes a HYBRID Patent Right other than as set forth in 7.11.2(a) above then only to the extent of the
scope of such exclusive license, HYBRID shall have the first right, at its sole cost and expense, to commence any Action.

 

    29 

     

    

 

CONFIDENTIAL

 

(c)              
The Party that has a first right to institute an Action pursuant to subsections (a) and (b) of this Section 7.11.2 shall be referred
to as the “Instituting Party”. The Instituting Party shall have sole control of any such Action including any settlement negotiations
in accordance with Section 7.11 and subject to the requirements of Section 7.11.7 (Settlement); provided, however, the other Party (the
 “Co-Party”) may, at its own expense, actively participate in the conduct of any such Action and, in any event, may provide
ongoing comments and advice regarding its position in the dispute which comments the Instituting Party shall consider in good faith.

 

7.11.3   
Co-Party Enforcement. If the Instituting Party does not commence an Action pursuant to Section 7.11.2 (Right to Institute
Action Regarding Infringing Activity) within twenty (20) calendar days of notice pursuant to Section 7.11.1 (Notification), then the Co-Party
shall have the right, at its sole cost and expense, to commence any Action that the Co-Party reasonably deems appropriate in accordance
with the terms of this Section 7.11 (Enforcement). The Co-Party shall, at its sole cost and expense, commence any action that the Co-Party
reasonably deems appropriate including notifying the infringer to cease and desist all such Infringing Activity, filing a complaint and
instituting a lawsuit.

 

		7.11.4	Paragraph IV Notices.

 

Each Party shall immediately give
written notice to the other of any certification of which it becomes aware filed pursuant to 21 U.S.C. § 355(b)(2)(A)(iv) or §
355(j)(2)(A)(vii)(IV) (or any amendment or successor statute thereto) claiming that any HYBRID Patent Right or HYBRID New Patents covering
any Product is invalid or that infringement will not arise from the development, manufacture, use or commercialization in the United States
of such Product by a Third Party. Upon the giving or receipt of such notice (provided such notice challenges a patent under which HYBRID
has any HYBRID Patent Right or that is a HYBRID New Patent and which same patent includes a claim that is directed solely to the composition
or formulation of the Product or a method of treating INDICATION by administration of the Product),
then METUCHEN shall have the first right, but not the obligation, to commence any applicable Action in the United States and only to the
extent of the scope of the licenses granted to METUCHEN under subsection (a)(i) of Section 2.1 (Grant of Licenses to METUCHEN).

 

		7.11.5	Joinder and Cooperation.

 

(a)              
Joinder. For any Action instituted by one Party, the other Party acknowledges and agrees that upon request of instituting
Party, such other Party shall join as necessary for standing to commence and maintain the Action.

 

(b)              
Cooperation. For any Action, METUCHEN and HYBRID shall use commercially reasonable efforts to assist and cooperate with
the Instituting Party.

 

    30 

     

    

 

CONFIDENTIAL

 

(c)                 Reimbursement.
The Instituting Party shall reimburse the Co-Party for: (1) any reasonable and pre-approved costs related to joining the Action
pursuant to subsection (a) above and (2) any costs related to assisting and cooperating with the Instituting Party pursuant to
subsection (b) above. Notwithstanding the foregoing, the Instituting Party shall have sole control of any such Action including any
settlement negotiations in accordance with Section 7.11.7 (Settlement).

 

7.11.6   
Recovery. Any damages, monetary awards or other amounts recovered, whether by judgment or settlement, pursuant to any suit,
proceeding or other legal action taken under this Section 7.11 (Enforcement) shall applied as follows:

 

(a)              
First, to reimburse the Parties for their respective costs and expenses (including reasonable attorneys’ fees and costs)
incurred in prosecuting such enforcement action; and

 

(b)
                Second, any amounts remaining shall be retained
by the Instituting

Party.

 

7.11.7   
Settlement. In the event any settlement of such an Action would, in any manner as determined by the Co-Party in its reasonable
discretion, reasonably affect any of the rights of the Co-Party under this Agreement, then prior to settling such Action with the infringing
Third Party(ies), the Instituting Party must first obtain the prior approval of the Co-Party only, which approval shall not be unreasonably
withheld or delayed as long as the rights of the Co-Party are not impaired, reduced, restricted or otherwise limited by such settlement
in which case the Co-Party shall have the sole and absolute right to deny or withhold approval of such settlement.

 

		8.	CONFIDENTIALITY.

 

8.1             
METUCHEN Confidential Information. HYBRID acknowledges and agrees that “METUCHEN Confidential Information” means
any materials, data, and information of any type whatsoever, in whatever form or media, whether or not marked as “confidential”
and/or “proprietary,” that is disclosed to or becomes known by HYBRID, and which is not generally known to the public or throughout
the trade, or which could reasonably be expected to be valuable to any of METUCHEN and its Affiliates or a competitor of any of METUCHEN
and its Affiliates including all the records of METUCHEN and any other secret, sensitive or confidential material related to the business
generally, including any information, work in progress, trade secrets, data or other secret, sensitive or confidential material, and any
business technology, business strategies, accounting, marketing, products, systems, formulae, practices, processes, customers or projects
of METUCHEN or its Affiliates that are created, accessed, viewed, learned, obtained, disclosed to or become known by HYBRID pursuant to
this Agreement including METUCHEN Work Product, and any information or matter subject to the terms of, or otherwise transmitted to METUCHEN
by HYBRID pursuant to, this Agreement. HYBRID shall: (a) hold such METUCHEN Confidential Information in strict confidence; (b) not disclose
such METUCHEN Confidential Information to any Third Party except as expressly permitted by this Agreement; and (c) use such METUCHEN Confidential
Information only as necessary for HYBRID’s performance of its obligations under this Agreement.

 

    31 

     

    

 

CONFIDENTIAL

 

8.2             
HYBRID Confidential Information. METUCHEN acknowledges and agrees “HYBRID Confidential Information” means any
materials, data, and information of any type whatsoever, in whatever form or media, whether or not marked as “confidential”
and/or “proprietary,” that is disclosed to or become known by METUCHEN and which is not generally known to the public or throughout
the trade, or which could reasonably be expected to be valuable to HYBRID and/or its Affiliates and/or a competitor of HYBRID and/or its
Affiliates including all the records of HYBRID and any other secret, sensitive or confidential material related to the business generally,
including any information, work in progress, trade secrets, data or other secret, sensitive or confidential material, and any business
technology, business strategies, accounting, marketing, products, systems, formulas, practices, processes, customers or projects of HYBRID
or its Affiliates that are created, accessed, viewed, learned, obtained disclosed to or become known by METUCHEN or its Affiliates during
the Term, but excluding any METUCHEN Confidential Information. METUCHEN shall: (a) hold such HYBRID Confidential Information in strict
confidence; (b) not disclose such HYBRID Confidential Information to any Third Party except as expressly permitted by this Agreement,
including to Third Parties that are performing services for METUCHEN or its Affiliates in connection with the activities of METUCHEN and
its Affiliates under the Agreement, provided that any such Third Party is subject to written obligations of confidentiality and nondisclosure
similar to those set forth in this Agreement protecting the HYBRID Confidential Information; and (c) use such HYBRID Confidential Information
only as necessary to perform the obligations of METUCHEN under this Agreement or otherwise develop and commercialize one or more Products
under this Agreement. METUCHEN may use and disclose the HYBRID Technology to its Affiliates and as necessary to sublicensees of METUCHEN
solely in accordance with the scope of the applicable licenses granted under Section 2.1 (Grant of Licenses to METUCHEN), provided that
any sublicensee is subject to written obligations of confidentiality and nondisclosure similar to those set forth in this Agreement protecting
the HYBRID Confidential Information and METUCHEN otherwise complies with its obligations under subsection (a)(1) of Section 2.3 (Sublicenses)
(the METUCHEN Confidential Information and the HYBRID Confidential Information collectively shall be referred to as the “Confidential
Information”).

 

8.3             
Exceptions to Confidential Information. As used herein, the term Confidential Information shall not include information:

 

(a)              
that is publicly available or later becomes available other than through a breach of this Agreement;

 

(b)              
subsequently lawfully obtained by the recipient from a Third Party without obligations of confidentiality with respect to such
Confidential Information; or

 

(c)              
already in the lawful possession of the recipient, as evidenced by written records, provided that such information was not acquired
directly or indirectly from the disclosure.

 

    32 

     

    

 

CONFIDENTIAL

 

8.4             
Disclosure Rights. Notwithstanding Sections 8.1 (METUCHEN Confidential Information) and 8.2 (HYBRID Confidential Information),
subject to the terms of this Section 8.4 (Disclosure Rights), either Party may disclose the other Party’s Confidential Information
in response to: (a) an order from a Governmental Authority; (b) in response to a Party in litigation, provided that an appropriate protective
order has been entered; or (c) if such disclosure is necessary to comply with any other Legal Requirements applicable to the disclosing
Party. If the receiving Party or any of its employees or agents are requested or required (by oral questions, interrogatories, requests
for information or documents in legal proceedings, subpoena, civil investigative demand or other similar process) to disclose any of
the Confidential Information of the disclosing Party, the receiving Party shall use commercially reasonable efforts not to disclose the
Confidential Information without providing the disclosing Party at least twenty-four (24) hours prior written notice of any such request
or requirement so that the disclosing Party may seek a protective order or other appropriate remedy and/or waive compliance with the
provisions of this Agreement; provided, however, to the extent a disclosure of Confidential Information is requested or required by a
Third Party (including Governmental Authority) during the pendency of a proceeding (e.g., hearing, deposition, etc.) without advance
notice of such request to the receiving Party but such Confidential Information is subject to a protective or other order or agreement
protecting the confidentiality of such Confidential Information, then the receiving Party shall have the right to disclose such Confidential
Information only to the extent requested or required and within the protection of the applicable order or agreement; provided further,
that the receiving Party shall so advise the disclosing Party of such disclosure as soon as reasonably practicable under the circumstances
to the extent permitted taking into consideration the nature of the proceedings. Notwithstanding the foregoing, the receiving Party shall
exercise its best efforts to preserve the confidentiality of the Confidential Information including by cooperating with the disclosing
Party to obtain an appropriate protective order or other reliable assurance that confidential treatment will be accorded the Confidential
Information by such tribunal. If the receiving Party becomes aware of any unauthorized use or disclosure of the Confidential Information
of the disclosing Party, the receiving Party shall promptly and fully notify the disclosing Party of all facts known to it concerning
such unauthorized use or disclosure.

 

8.5             
Ownership of Confidential Information. Except as provided in this Agreement, Confidential Information furnished by either
Party under the Agreement shall remain the disclosing Party’s property.

 

8.6             
No Licenses or Other Rights. The Parties hereby agree that no right or license under any patent, copyright, trademark or
other intellectual property right is granted, or is construed to be granted, to either Party except as provided by the terms and conditions
of this Agreement.

 

		9.	INDEMNIFICATION AND INSURANCE.

 

9.1              Indemnification
by HYBRID. Subject to the terms of Section 9.3 (Procedures for Indemnification), HYBRID shall indemnify, defend and hold
METUCHEN, its Affiliates and their respective directors, officers, shareholders, employees, representatives, agents, successors and
permitted assigns (“METUCHEN Indemnified Parties”) harmless from and against any and all any and all Third Party
liabilities, losses, claims, demands, obligations, judgments, causes of action, assessments, fines, damages, costs and expenses
(including reasonable attorneys’ fees) (collectively, “Third Party Claims”), that arise out of or in connection
with: (a) a breach or inaccuracy of any representation, warranty or covenant made by HYBRID in Section 5 (Representations,
Warranties and Covenants) of this Agreement; (b) a material breach of this Agreement by HYBRID; (c) any negligence, willful or
reckless actions or misconduct of HYBRID, its Affiliates or any of their respective employees, agents or subcontractors; (d) any
personal injury, including death, or damage to tangible property caused by the negligent or intentional acts of HYBRID, its
Affiliates or any of their respective employees, agents or subcontractors; and (e) any breach of HYBRID’s confidentiality
obligations under Section 8 (Confidentiality) (f) any claims by any third parties, including but not limited to private parties and
governmental agencies relating to products sold or distributed by HYBRID, or to marketing or promotional efforts by HYBRID,
including by any agents, licensees or contracting parties of HYBRID. Notwithstanding the foregoing, HYBRID shall not be liable for
any Third Party Claims to the extent caused by negligent or willful acts or omissions of the METUCHEN Indemnified Parties.

 

    33 

     

    

 

CONFIDENTIAL

 

9.2             
Indemnification by METUCHEN. Subject to the terms of Section 9.3 (Procedures for Indemnification), METUCHEN shall indemnify,
defend and hold HYBRID, its Affiliates and their respective directors, officers, shareholders, employees, representatives, agents, successors
and permitted assigns (“HYBRID Indemnified Parties”) harmless from and against any and all Third Party Claims, that arise
out of or in connection with: (a) a breach or inaccuracy of any representation, warranty or covenant made by METUCHEN in Section 5 (Representations,
Warranties and Covenants) of this Agreement; (b) a material breach of this Agreement by METUCHEN; (c) any negligence, willful or reckless
actions or misconduct of METUCHEN, its Affiliates or any of their respective employees, agents or subcontractors; (d) any personal injury,
including death, or damage to tangible property caused by the negligent or intentional acts of METUCHEN, its Affiliates or any of their
respective employees, agents or subcontractors; (e) any breach of METUCHEN’s confidentiality obligations under Section 8 (Confidentiality);
and (f) any claim by a Third Party that the use, manufacture, sale, offer for sale or import of the Product in the Territory with respect
to the METUCHEN Technology infringes upon, misappropriates or results from the misappropriation of, or violates the intellectual property
or proprietary rights of a Third Party. Notwithstanding the foregoing, METUCHEN shall not be liable for any Third Party Claims to the
extent caused by negligent or willful acts or omissions of the HYBRID Indemnified Parties.

 

		9.3	Procedures for Indemnification.

 

9.3.1       
General. In connection with any Third Party Claims or action for which a Party seeks indemnification (“Indemnified
Party”) from the other Party (“Indemnifying Party”) in accordance with this Section, the Indemnified Party: (a) shall
give the Indemnifying Party prompt written notice of the claim or action; provided, however, that failure to provide such
notice shall not relieve the Indemnifying Party from its liability or obligation hereunder, except to the extent of any material prejudice
as a direct result of such failure; (b) shall cooperate with the Indemnifying Party, at the Indemnifying Party’s expense, in connection
with the defense and settlement of the Third Party Claim; and (c) shall permit the Indemnifying Party to control the defense and settlement
of the Third Party Claim; provided, however, that the Indemnifying Party may not settle the Third Party Claim without the
Indemnified Party’s prior written consent, which shall not be unreasonably withheld or delayed, in the event such settlement: (y)
materially adversely impacts the Indemnified Party’s rights; or (z) arises out of or is a part of any criminal action, suit or proceeding
or contains a stipulation or admission or acknowledgement of any liability or wrongdoing (whether in contract, tort or otherwise) on the
part of the Indemnified Party. Further, the Indemnified Party, at its cost, may participate in the defense of the Third Party Claim through
counsel of its own choosing.

 

    34 

     

    

 

 

CONFIDENTIAL

 

9.3.2       
Contributory Negligence; Right of Contribution. Nothing contained herein shall bar a claim for contributory negligence or
a Party’s right of contribution.

 

9.3.3       
Right to Withhold Payments. During the time in which a Third Party Claim is pending, the Indemnified Party shall have the
right to withhold any payments due to the Indemnifying Party until such time as the Third Party Claim has been settled or a final, non-
appealable order of a court of competent jurisdiction has been entered with respect to such Third Party Claim, in which case the Indemnified
Party shall pay the Indemnifying Party any withheld amounts less any amounts that the Indemnified Party may be required to pay, on behalf
of the Indemnifying Party, with respect to any such settlement or judgment.

 

9.4              Insurance.
Each Party shall maintain in effect at all times during the Term of this Agreement insurance with (a) a carrier with an A.M. Best
rating of A-X or better with respect to HYBRID and (b) with a carrier with an A.M. Best rating of A-X or better with respect to
METUCHEN. Such insurance shall include worker’s compensation in statutory amounts with respect to METUCHEN) and/or Employers
Liability Insurance Policy as customary, product liability, errors and omissions, and general liability insurance in amounts not
less than $2 million per occurrence and $4 million annual aggregate for all claims against all losses, claims, demands, proceedings,
damages, costs, charges and expenses for injuries or damage to any person or property arising out of or in connection with each
Party’s activities under this Agreement. Both Parties shall designate the other Party and its Affiliates as “additional
insureds” in respect of its liability (i.e., the additional insureds’ liability) for any act and/or omission of
the primary insured on products/completed operations liability and general liability policies. Each Party shall, on or before the
Effective Date and thereafter upon the other Party’s reasonable request, provide the other Party with certified copies of all
applicable endorsements and certificates of insurance, both evidencing such coverage, which shall also state that such other Party
shall be provided a minimum of thirty (30) calendar days prior written notice of any cancellation and of any change in material
terms of coverage. Upon a Party’s request, the other Party also shall provide the requesting Party with certified copies of
the involved insurance policy or policies within fifteen (15) calendar days of such request. Each Party shall obtain or otherwise
arrange for appropriate levels of insurance coverage for all subcontractors performing work under this Agreement. Each Party shall
maintain, in its files, evidence of all subcontractors’ insurance coverage and shall provide proof of such coverage to the
other Party upon such Party’s request. In the event coverage is denied or reimbursement of a properly presented claim is
disputed by the carrier for insurance provided as described above, upon written request from a Party, the other Party shall provide
the requesting Party with a certified copy of the involved insurance policy or policies within ten (10) business days of receipt of
such request. All notices and copies of policies, endorsements, certificates and other proof of coverage obtained by a Party as
required under this Section shall be sent to the other Party at the addresses set forth in Section 12.5 (Notices). The terms of this
Section shall not be deemed to limit the liability of a Party hereunder, or to limit any rights a Party may have including rights of
indemnity or contribution.

 

		10.	LIMITATION ON LIABILITY.

 

10.1      
General. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR LOST PROFITS, PUNITIVE, INDIRECT, INCIDENTAL, EXEMPLARY,
SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND (INCLUDING LOST PROFITS0 ARISING OUT OF, OR IN CONNECTION WITH, THIS AGREEMENT.

 

    35

     

    

 

CONFIDENTIAL

 

10.2      
Exclusions from Limitations of Liability. Notwithstanding anything contained herein to the contrary, the limitations
of liability contained in this Section 10 (Limitation on Liability) shall not apply to obligations to indemnify for third party claims
under Section 9.

 

		11.	DISPUTE RESOLUTION.

 

11.1         
Executive-Level; Arbitration. In the event of any dispute, controversy or claim arising out of or relating to this Agreement,
or the breach thereof, upon written notice of such dispute by either Party, the senior executive officers of METUCHEN and HYBRID shall
meet to conduct face-to-face negotiations in an effort to resolve the dispute within ten (10) days of receipt of written notice. If these
representatives are unable to resolve the dispute within ten (10) calendar days after the Parties have been notified in writing of the
dispute, any unresolved dispute, controversy or claim shall be determined exclusively (subject to Section 11.3 (Equitable Relief) below)
by an arbitration administered by the American Arbitration Association (“AAA”). The number of arbitrators shall be one (1)
The arbitrator shall be selected in accordance with the AAA Arbitration Rules. The place of arbitration shall be New York City, New York.

 

11.2         
Continued Performance. Except where clearly prevented by the issue in dispute, both Parties shall continue performing their
obligations under this Agreement while the dispute is being resolved under this Section 11 (Dispute Resolutions) unless and until the
dispute is resolved or until this Agreement is terminated as provided herein.

 

11.3         
Equitable Relief. Notwithstanding anything contained in this Agreement to the contrary, either Party shall have the right
to apply to any court of competent jurisdiction for provisional relief, including pre-arbitral attachments, a temporary restraining order,
temporary injunction, permanent injunction and/or order of specific performance, as may appear reasonably necessary to preserve the rights
of either Party. The application of either Party to a judicial authority for such measures shall not be deemed to be an infringement or
a waiver of the arbitration agreement and shall not affect the relevant powers reserved to the arbitrators.

 

11.4         
Governing Law; Venue. This Agreement, and all the rights and duties of the Parties arising from or relating in any way to
the subject matter of this Agreement or the transaction(s) contemplated by it, shall be governed by, construed and enforced in accordance
with the laws of the State of New York (excluding any conflict of laws provisions that would refer to and apply the substantive laws of
another jurisdiction), except that issues relating to this arbitration clause and any arbitration hereunder shall be governed by the Federal
Arbitration Act, Chapter 1 and 2.

 

11.5         
Confidentiality. Except as may be required by law, neither Party nor its representatives nor a witness nor an arbitrator
may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both Parties.

 

11.6          Fees
and Expenses. The arbitrators shall award to the prevailing Party, if any, as determined by the arbitrators, all of its Costs
and Fees. “Costs and Fees” means all reasonable pre- award expenses of the arbitration, including the arbitrators’
fees, administrative fees, travel expenses, out of pocket expenses such as copying and telephone, court costs, witness fees and
attorneys’ fees, as well as interest as permitted by New York law.

 

    36

     

    

 

CONFIDENTIAL

 

11.7         
Punitive Damages. Consistent with AAA International Arbitration Rules, the arbitrator shall not award punitive or exemplary
damages.

 

11.8        
Discovery/Document Exchange. Any discovery or document exchange shall be conducted in accordance with the AAA Guidelines
for Arbitrators Concerning Exchanges of Information. Consistent with Guideline 6(b), the arbitrator shall not permit depositions, interrogatories,
or requests for admission.

 

11.9         
Executive Level Negotiation. At any time prior to or after the demand for arbitration is filed, either Party may request
of the other Party executive level Negotiation. The Parties shall arrange a meeting of executive-level employee(s) within ten (10) days
of such request; the ICDR and the arbitrator are empowered to stay proceedings pending the outcome of such negotiations; provided, however,
that such a stay shall not exceed thirty (30) calendar days.

 

		12.	MISCELLANEOUS.

 

		12.1	Assignment.

 

(a)           Neither Party may assign nor delegate (except as
permitted by Section 2.2 (Sublicenses)) this Agreement, or any part thereof, to a Third Party by operation of law or otherwise
without the prior written consent of the other Party, which consent will not be unreasonably withheld, delayed or conditioned;
provided, however, that without the consent of the other Party: (1) HYBRID shall have the right to assign this Agreement to a
successor to all or substantially all of the business to which this Agreement relates; and (2) METUCHEN shall have the right to
assign this Agreement to any Affiliate of equal or greater financial viability to METUCHEN or to a successor to all or substantially
all of the business to which this Agreement relates.

 

(b)           To
the extent that HYBRID requests that the Agreement be assigned to an Affiliate of HYBRID, HYBRID acknowledges that METUCHEN’s consent
may be conditioned on HYBRID guaranteeing in a written agreement with METUCHEN the performance of the HYBRID Affiliate and, to the extent
HYBRID remains the owner of any of the HYBRID Technology, ensuring that such assignment does not adversely impact the rights of METUCHEN
under the Agreement with respect to the licenses and ownership rights granted to METUCHEN under the Agreement.

 

(c)           The
assigning Party shall notify the other Party of any permitted assignment under this Section promptly after the assignment has been completed.
Any assignment or delegation in circumvention of the foregoing provisions of this Section shall be void. Subject to the foregoing, this
Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective permitted successors and assigns.

 

    37

     

    

 

CONFIDENTIAL

 

(d)           Notwithstanding
the foregoing, any Third Party to which this Agreement and the obligations hereunder may be assigned pursuant to this Section must agree,
as a condition to such assignment, to be bound by the terms and conditions of this Agreement.

 

12.2         
Benefits of Agreement. The licenses and other rights granted to METUCHEN or HYBRID under this Agreement extend to present
and future Affiliates of METUCHEN or HYBRID (as appropriate) subject to the terms and conditions of this Agreement; provided, however,
that a Party to this Agreement shall have the right to revoke, terminate or otherwise limit such licenses or rights as relates to one
of its own Affiliates.

 

		12.3	Media Releases and Public Disclosures of Agreement.

 

12.3.1   
No Release. Subject to Section 12.3.2 (Security Laws Compliance), neither Party shall issue or make any media release or
public announcement (including any announcements made via any posting on the Internet), or disclosure subject to Regulation FD promulgated
under the Securities Exchange Act of 1934, as amended, or other similar publicity announcing the existence of this Agreement or relating
to any term or condition of this Agreement or the relationships created by this Agreement without three (3) Business Days’ prior
written notice to the other Party and the prior written agreement of the other Party. Notwithstanding the foregoing, each Party shall
be permitted to disclose the terms of this Agreement to a potential or actual investor or purchaser of such Party, or to an investment
bank retained for the purpose of identifying and facilitating a transaction with a potential investor or purchaser of such Party, provided
that (a) in the case of disclosures by HYBRID, such disclosures shall not be to competitors of METUCHEN and its Affiliates and (b) any
disclosure must be subject to a written agreement with the applicable Third Party protecting the confidentiality of such information.

 

12.3.2    Security
Laws Compliance. Each Party acknowledges that the other Party may, upon advice of its legal advisors, be required by applicable
securities laws and/or stock exchange rules to issue a public statement regarding the existence of this Agreement and/or file a copy
of this Agreement with its applicable securities regulators. The Party required to make any such filing or disclosure shall, upon
the request of the other Party, furnish to such other Party a legal opinion from its legal advisors indicating that such Party is
subject to such filing and/or disclosure requirement. If a Party is required to so file a copy of the Agreement or disclose the
existence or content or information regarding this Agreement, it shall: (a) use all commercially reasonable efforts to ensure that
only such information is disclosed as is absolutely necessary to meet the applicable filing and/or disclosure requirements; and (b)
provide a copy of such proposed public statement or disclosure to the other Party along with a copy of any application for
confidential treatment to be submitted therewith, for review in as far in advance of the required filing date as is reasonably
practicable. Upon any reasonable objection to such public statement or disclosure by the other Party, the Parties shall work in good
faith to resolve the issues giving rise to such objection, including redacting portions of such public statement or disclosure as
mutually agreed by the Parties. Each Party shall act in a timely and responsive manner in order to meet the other Party’s
filing requirements to timely meet its filing and disclosure obligations. The Parties acknowledge and mutually agree that this
Section is not intended to, and shall not be used by either Party as a means to, circumvent the general restrictions set forth in
subsection (a) above.

 

    38

     

    

 

CONFIDENTIAL

 

12.3.3   
Approvals, Consents or Notices. Any approvals, consents or notices required by this Section shall be made or sent as follows:
(a) with respect to METUCHEN, METUCHEN’s Chief Executive Officer; and (b) with respect to HYBRID, HYBRID’s Chief Executive
Officer.

 

12.4         
Force Majeure. In the event a Party’s performance of its obligations under this Agreement is delayed or prevented
by Force Majeure, the non-performing Party shall, upon giving written notice to the other Party, be excused from such performance to the
extent of such prevention, restriction, interference or delay, provided that the non-performing Party shall use its reasonable best efforts
to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed.
When such circumstances arise, the Parties shall discuss what, if any, modifications of the terms of this Agreement may be required in
order to arrive at an equitable solution. Notwithstanding the foregoing, if the period of any previous actual non-performance of a Party
because of Force Majeure conditions plus the anticipated future period of non-performance because of such conditions will exceed an aggregate
of one hundred twenty (120) days, then the Party unaffected by such event may terminate this Agreement for an Event of Default by not
less than sixty (60) days written notice of termination to the other Party; provided that, if the Force Majeure event ceases within such
sixty (60) day period, this Agreement shall remain in full force and effect.

 

12.5         
Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon
personal delivery to the Party to be notified; (b) when sent by confirmed facsimile if sent during regular business hours of the recipient,
if not, then on the next business day; (c) five (5) days after having been sent by registered or certified mail, return receipt requested,
postage prepaid; or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the addresses set forth below or at such other address as HYBRID or METUCHEN,
respectively, may designate by ten (10) days advance written notice to the other Party.

 

If to HYBRID, to: Harold Hoium,
5200 Wilson Road, Suite 150, Edina, MN 55424

 

If to METUCHEN, to:1 Greg Ford, 200 US Hwy 9, Suite 500, Manalapan, NJ 07726

 

12.6          Execution
of Additional Documents. Each Party hereto agrees to execute such further papers or agreements as may be reasonably necessary or
desirable to effect the purpose of this Agreement and the schedules attached hereto and carry out their respective provisions and terms.

 

12.7          No Waiver of Rights. No failure or delay on the part of either Party in the exercise of any power or right under the Agreement
shall operate as a waiver thereof. No single or partial exercise of any right or power under the Agreement shall operate as a waiver of
such right or of any other right or power. The waiver
by either Party of a breach of any provision of the Agreement shall not operate or be construed as a waiver of any other or subsequent
breach under the Agreement.

 

 

1 NTD: to be completed by
the parties

 

    39

     

    

 

CONFIDENTIAL

 

12.8         
Severability. In case any one or more of the provisions contained in the Agreement shall, for any reason be held to be invalid,
illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability, shall not affect any other provision of the
Agreement, but the Agreement shall be construed as if such invalid, illegal, or unenforceable provision or provisions had never been contained
in the Agreement, unless the deletion of such provision or provisions would result in such a material change as to cause completion of
the transactions contemplated in the Agreement to be impossible and provided that the performance required by the Agreement with such
clause deleted remains substantially consistent with the intent of the Parties.

 

		12.9	Construction.

 

(a)            The
Section captions in this Agreement have been inserted as a matter of convenience and are not part of this Agreement.

 

(b)             Wherever any provision of the Agreement uses the terms “include,” “includes,” or “including”,
such term shall be deemed to mean “include, without limitation,” “includes, without limitation” and “including,
without limitation” or “include, but not limited to,” “includes, but not limited to,” or “including,
but not limited to.”

 

(c)              
Any reference to “days” means calendar days unless otherwise specified in the Agreement.

 

(d)              
The recitals set forth at the start of the Agreement, along with the Schedules, Exhibits, Attachments and Addenda to the Agreement,
and the terms and conditions incorporated in such recitals, Schedules, Exhibits, Attachments and Addenda shall be deemed integral parts
of the Agreement, are hereby incorporated by reference and all references in the Agreement to the “Agreement” shall encompass
such recitals, Schedules, Exhibits, Attachments and Addenda and the terms and conditions incorporated in such recitals, Schedules, Exhibits,
Attachments and Addenda.

 

(e)              
Unless otherwise explicitly stated, in the event of any conflict between the terms and conditions of the main body of the Agreement
and the terms and conditions of any of the Schedules, Exhibits, Attachments or Addenda to the Agreement, the terms and conditions of the
main body of the Agreement shall prevail.

 

(f)               
Any terms and conditions that may be set forth in any invoice or order form (other than quantities and prices consistent with the
Agreement) are void and of no force and effect.

 

(g)               This
Agreement has been prepared jointly and shall not be strictly construed against either Party. The Parties agree that any rule of
construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction
or interpretation of the Agreement.

 

    40

     

    

 

(h)              
The masculine, feminine or neuter gender and the singular or plural number shall each be deemed to include the others whenever
the context so indicates.

 

(i)                
Except as otherwise expressly set forth in the Agreement, under no circumstances does a Party to the Agreement, as a result of
the Agreement, or due to the financing by it of any activity performed by the other Party under this Agreement, obtain any ownership interest
in or other right or license to any technology, regulatory submissions or intellectual property of the other Party, including items owned,
acquired, licensed or developed by the other Party, or transferred by the other Party to such Party at any time pursuant to the Agreement.

 

(j)                
Unless otherwise set forth in the Agreement, all references to Sections, Exhibits, Attachments, Addenda and Schedules in the Agreement
are to Sections, Exhibits, Attachments, Addenda and Schedules of and to the Agreement.

 

12.10     
Counterparts. The Agreement, or any part thereof requiring signing by the Parties, may be executed in two or more counterparts,
each of which shall be an original as against any Party whose signature appears thereon but both of which together shall constitute one
and the same instrument. A facsimile transmission of the signed Agreement, and those parts thereof requiring signing by the Parties, shall
be legal and binding on both Parties.

 

12.11     
Amendments. No amendment or modification of or supplement to the terms of this Agreement or the schedules attached hereto
shall be binding on either Party unless reduced to writing and signed by both Parties.

 

12.12     
Entire Agreement. This Agreement, together with all of the Schedules, Exhibits, Attachments and Addenda hereto, sets forth
the entire, final and exclusive agreement between the parties as to the subject matter hereof and supersedes all prior and contemporaneous
agreements, understandings, negotiations and discussions, whether oral or written, between the parties. For the avoidance of doubt, this
Agreement supersedes the Confidential Disclosure Agreement, dated June 15, 2011, it being acknowledged and agreed by the Parties that
any Confidential Information of a Party disclosed thereunder shall be subject to the confidentiality and non-disclosure terms and conditions
set forth in this Agreement. The Recitals are hereby incorporated into this Agreement by this reference. This Agreement may be modified
only pursuant to a writing executed by authorized representatives of the Parties.

 

[Remainder of Page Left
Intentionally Blank]

 

    41

     

    

 

IN WITNESS WHEREOF, the Parties have caused
this Agreement to be executed by their duly authorized representatives as of the Effective Date.

 

	 	HYBRID.	 	METUCHEN
	 	 	 	 
	 	By:	/s/ Harold Hoium	 	By:	/s/ Greg Ford 
	 	Name:	Harold Hoium 	 	Name: 	J. Gregory Ford
	 	 	 	 
	 	March 24, 2020	 	March 24, 2020

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]